

PCT

Date: July 28, 2005 I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chano et al.) Examiner: Unassigned
)
 Application No.: 10/516,558) Group Art Unit: Unassigned
)
 Filed: November 30, 2004) Confirmation No.: Unassigned
)
 Docket No.: 3190-070) Customer No.: 33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 28, 2005

Dear Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office dated July 11, 2005, it is respectfully submitted that the English translation of the application, the declaration of the inventors, and a copy of the "sequence listing" in computer readable form was previously submitted on January 25, 2005, via Express mail service, as evidenced by the enclosed copy of applicant's PTO date-stamped post card. A copy of the previous response (except a copy of the diskette) is also enclosed. January 25, 2005 is the date that should be reflected in the file for satisfying all requirements under 35 U.S.C. § 371.

In the event that any fees are due with this paper, please charge Deposit Account No. 50-0925.

Respectfully submitted,

Luke A. Kilyk
Luke A. Kilyk
Reg. No. 33,251

Docket No.: 3190-070
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/516,558	Tokuhiro Chano	3190-070
R E C E I V E D		INTERNATIONAL APPLICATION NO.
		PCT/JP03/00882
JUL 13 2005		LA. FILING DATE
KILYK & BOWERSOX, P.L.L.C.		PRIORITY DATE
01/30/2003		
CONFIRMATION NO. 2830		
371 FORMALITIES LETTER		
OC000000016489947		

Date Mailed: 07/11/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 11/30/2004
- Copy of the International Search Report filed on 11/30/2004
- Copy of IPE Report filed on 11/30/2004
- Biochemical Sequence Listing filed on 11/30/2004
- U.S. Basic National Fees filed on 11/30/2004
- Priority Documents filed on 11/30/2004

Docketed

Due Date 9/11/05 & 9/30/05

Dkt No 3190-070

By JMB

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Translation of the application into English. Note a processing fee will be required if submitted later than 30 months from the priority date. 7/30/05
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

BEST AVAILABLE COPY

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/516,558	PCT/JP03/00882	3190-070

FORM PCT/DO/EO/905 (371 Formalities Notice)

BEST AVAILABLE COPY

RECEIVED
FEB 09 2005

KILYK & BOWERSOX, P.L.L.C.

DT07 Rec'd PCT/PTO 25 JAN 2005

U.S. Patent Application No. 10/516,558

Docket No. 3190-070

Filed: November 30, 2004

Applicant: CHANO et al.

Entitled: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

Papers filed herewith on: January 25, 2005

Transmittal Letter Concerning Filing Under 35 U.S.C. 371; English translation of the International Application; Preliminary Amendment (9 pages), Statement under 3 C.F.R. § 1.821, Computer-readable diskette; Executed Declaration; Information Disclosure Statement; Form PTO-1449, 4 documents, and Credit Card Payment Form.

Express Mail Label: EV567259572US
COMMISSIONER FOR PATENTS

Receipt is hereby acknowledged of the papers filed as indicated in connection with the above-identified case

LAK/khb

COPY

DOCKETED

DUE DATE

DKT NO. 3190-070

BY JMB

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER
3190-070**U.S. APPLICATION NO. (If known. see 37 CFR 1.5)**
10/516,558**INTERNATIONAL APPLICATION NO.**
PCT/JP03/00882**INTERNATIONAL FILING DATE**
January 30, 2003**PRIORITY DATE CLAIMED**
June 3, 2002**TITLE OF INVENTION:** RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE**APPLICANT(S) FOR DO/EO/US:** Tokuhiro CHANO, Hidetoshi OKABE, and Shiro IKEGAWA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2))
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 34 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 34 (35 U.S.C. 371(c)(3))
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

COPY**Items 11 to 20 below concern document(s) or information included:**

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An Application Data Sheet under 37 CFR 1.76
15. A substitute specification.
16. A power of attorney and/or address change letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information:

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/516,558		INTERNATIONAL APPLICATION NO. PCT/JP03/00882		ATTORNEY'S DOCKET NUMBER 3190-070																					
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <table> <tr> <td><input type="checkbox"/></td> <td>a) Basic national fee</td> <td>\$300.00</td> <td>\$ 0.00</td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>b) Examination fee</td> <td>\$200.00</td> <td>\$ 0.00</td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>c) Search fee</td> <td>\$500.00</td> <td>\$ 0.00</td> <td></td> </tr> <tr> <td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 0.00</td> <td>\$ 0.00</td> </tr> </table> <p><input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.</p>						<input type="checkbox"/>	a) Basic national fee	\$300.00	\$ 0.00		<input type="checkbox"/>	b) Examination fee	\$200.00	\$ 0.00		<input type="checkbox"/>	c) Search fee	\$500.00	\$ 0.00		TOTAL OF ABOVE CALCULATIONS =			\$ 0.00	\$ 0.00
<input type="checkbox"/>	a) Basic national fee	\$300.00	\$ 0.00																						
<input type="checkbox"/>	b) Examination fee	\$200.00	\$ 0.00																						
<input type="checkbox"/>	c) Search fee	\$500.00	\$ 0.00																						
TOTAL OF ABOVE CALCULATIONS =			\$ 0.00	\$ 0.00																					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)																							
87 - 100 =	/50 =	0		x \$250.00	\$ 0.00																				
Surcharge of \$130.00 for furnishing the oath or declaration later than Months from the earliest claimed priority date (37 CFR 1.492(e)).																									
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																						
Total claims	26 - 20 =	6	x \$50.00	\$ 300.00																					
Independent claims	1 - 3 =	0	x \$200.00	\$ 0.00																					
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00	\$																				
TOTAL OF ABOVE CALCULATIONS =				\$ 300.00																					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.																									
SUBTOTAL = \$ 300.00																									
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).																									
TOTAL NATIONAL FEE = \$ 300.00																									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 0.00																									
TOTAL FEES ENCLOSED = \$ 300.00																									
<table> <tr> <td>Amount to be: Refunded</td> <td>\$</td> </tr> <tr> <td>Amount to be: Charged</td> <td>\$</td> </tr> </table>						Amount to be: Refunded	\$	Amount to be: Charged	\$																
Amount to be: Refunded	\$																								
Amount to be: Charged	\$																								
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-0925</u>.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>																									
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO</p> <p>KILYK & BOWERSOX, P.L.L.C. 53 A East Lee Street Warrenton, VA 20186</p> <p>Phone (540) 428-1701 - Facsimile (540) 428-1720</p>																									
<p>SIGNATURE: </p> <p>Luke A. Kilyk NAME</p> <p>33,251 REGISTRATION NUMBER</p>																									

RB1 GENE-INDUCED PROTEIN (RB1CC1) AND GENE

Technical Field

The present invention relates to a novel protein and
5 polypeptide (hereunder, referred to as "novel protein RB1CC1") that can induce expression of a tumor-suppressor gene (retinoblastoma gene: RB1 gene). More specifically, the present invention relates to a polypeptide having all or a part of an amino acid sequence of a novel protein, a
10 nucleic acid (hereunder, referred to as "RB1CC1 gene") coding for the polypeptide, a recombinant vector containing the nucleic acid, a transformant that was transformed with the recombinant vector, a method for producing a peptide or polypeptide using the transformant, an antibody against the
15 peptide or polypeptide, a method of screening for compounds that utilizes these, the screened compounds, an activity-inhibiting compound or activity-enhancing compound that acts on the polypeptide or the nucleic acid, a pharmaceutical composition relating to these, and a method
20 of testing or diagnosing a disease relating to these as well as a reagent.

Background of the Invention

Multidrug resistance (MDR) that is resistance to
25 treatment with anticancer agents is a major barrier to the successful treatments of cancer. While current

understanding of factors that contribute to origins of MDR is limited, it is considered that P-glycoprotein that is a product of an MDR-associated gene (MDR1 gene) is involved in several cancers. It is also known that in other cancers expression of P-glycoprotein correlates inversely with emergence and metastasis of the cancer. It is considered that these different effects of P-glycoprotein are subject to suppression by different gene products or conduct different interactions. The identification of genes associated with MDR is essential in order to clarify these phenomena.

Summary of the Invention

A problem to be solved by the present invention is to discover a gene associated with multidrug resistance to anticancer agents as described above and the gene product thereof. More specifically, an object of the present invention is to provide a novel protein and polypeptide (novel protein RB1CC1) that can induce expression of the tumor-suppressor gene (retinoblastoma gene: RB1 gene). Another object of the present invention is to provide the nucleic acid (hereunder, "RB1CC1 gene") coding for all or the part of the amino acid sequence of the novel protein, and the method for producing the protein or polypeptide (novel protein RB1CC1) using genetic engineering techniques. A further object of the present invention is to provide the

antibody against the polypeptide derived from the novel protein RB1CC1. Other objects of the present invention are to conduct screening for an inhibitor, antagonist, or activator for actions of the novel protein RB1CC1 utilizing the aforementioned substances, to provide screened compounds, and to provide the pharmaceutical composition for use in treatment of multidrug resistance (MDR) that is resistance to treatment with anticancer agents utilizing these. Another problem to be solved by the present invention is to provide the method for diagnosing a cancer cells or cancer by testing for the novel protein and polypeptide (RB1CC1 protein) that can induce expression of the tumor-suppressor gene (retinoblastoma gene: RB1 gene) or the nucleic acid (hereunder, "RB1CC1 gene") coding for all or a part of the amino acid sequence of the protein, that were clarified in the present invention. A further object of the present invention is to provide nucleic acid primers that can amplify a nucleic acid coding for all or the part of the amino acid sequence of the protein, and to provide the method for diagnosing cancer cells or cancer by testing for an amplification product of the nucleic acid using primers. A still further object of the present invention is to provide the antibody that can react with the protein or polypeptide (RB1CC1 protein), as well as an immunological assay method that uses the antibody. A further object of the present invention is to provide an assay reagent or kit

that uses the primers or the antibody to be used in the assay method.

In order to solve the above problems, the present inventors identified a gene expressing differentially in U-2 OS osteosarcoma cells and MDR-variant induced cells and determined the nucleotide sequence thereof and the amino acid sequence encoded by cDNA of the novel protein. Further, in order to verify that a similar protein is present in animals, inventors determined the amino acid sequence of a novel protein in mouse and the amino acid sequence encoded by cDNA of the novel protein. In addition, inventors prepared antibodies that recognize these proteins and conducted immunological assay in addition to assay of expression, mutation, deletion and the like for the gene, and found that expression of the gene and expression of the protein are suppressed in certain kinds of cancer cells, thereby completing the present invention.

That is, the present invention comprises the following:

1. A protein or polypeptide which is present in the nucleus of human or animal cell and which has a function that can induce a transcription factor function and/or expression of retinoblastoma gene (RB1 gene) or a gene product thereof.
2. The human protein according to the above 1, which is a polypeptide or protein selected from the group consisting

of: (1) a polypeptide or protein represented by an amino acid sequence described in SEQ ID No: 1 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the said polypeptide or protein; (3) a polypeptide or protein having homology of at least approximately 70% at the amino acid sequence level with the said polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).

3. The animal protein according to the above 1 that is a protein derived from mouse, which is a polypeptide or protein selected from the group consisting of: (1) a polypeptide or protein represented by an amino acid sequence described in SEQ ID No: 2 in the sequence listing; (2) a polypeptide comprising at least five amino acids of the amino acid sequence of the said polypeptide or protein; (3) a polypeptide or protein having homology of at least approximately 70% at the amino acid sequence level with the said polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the said polypeptide or protein according to any one of the preceding (1) to (3).

4. A nucleic acid coding for the polypeptide or protein according to any one of the above 1 to 3, or a complementary strand thereof.
5. A nucleic acid hybridizing under stringent conditions with the nucleic acid or the complementary strand thereof according to the above 3.
6. A nucleic acid represented by a base sequence comprising at least 15 consecutive bases of the base sequence of a nucleic acid described in SEQ ID No: 3 to 4 in the sequence listing or a complementary strand thereof, wherein a polypeptide expressed by transcription of the nucleic acid is the polypeptide according to any one of the above 1 to 3.
7. A recombinant vector containing the nucleic acid according to any one of the above 4 to 6.
- 15 8. A transformant that was transformed with the recombinant vector according to the above 7.
9. A method for producing the polypeptide or protein according to any of the above 1 to 3, comprising a step of culturing the transformant according to the above 8.
- 20 10. Nucleic acid primers represented by SEQ ID Nos: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid or the complementary strand thereof according to any one of the above 4 to 6.
11. An antibody that immunologically recognizes the polypeptide or protein according to any one of the above 1 to 3.

12. A method of screening for compounds that inhibit or enhance a function that can induce transcription factor activity of the polypeptide or protein and/or expression of RB1 gene according to any of the above 1 to 3, wherein
5 the method uses at least one member of the group consisting of the polypeptide or protein according to any one of the above 1 to 3 and the antibody according to the above 11.

13. A method of screening for compounds that interact with the nucleic acid according to the above 4 or 6 to inhibit
10 or enhance expression of the nucleic acid, wherein the method uses at least one member of the group consisting of the nucleic acid according to any one of the above 4 to 6, the vector according to the above 7, the transformant according to the above 8, and the nucleic acid primers according to the above 10.

15. 14. A compound that was screened by the screening method according to the above 12 or 13.

15. A compound that inhibits or enhances a function that can induce transcription factor activity and/or expression of RB1 gene of the polypeptide or protein according to any
20 of the above 1 to 3.

16. A compound that interacts with the nucleic acid according to any one of the above 4 to 6 to inhibit or enhance expression of the nucleic acid.

17. A pharmaceutical composition for use in treatment of
25 multidrug resistance that is resistance to treatment with anticancer agents, wherein the pharmaceutical composition

comprises at least one member of the group consisting of the polypeptide or protein according to any of the above 1 to 3, the nucleic acid according to any one of the above 4 to 6, the vector according to the above 7, the transformant 5 according to the above 8, the nucleic acid primers according to the above 10, the antibody according to the above 11, and the compound according to any one of the above 14 to 16.

18. A method of testing or diagnosing a disease related with 10 expression or activity of the polypeptide or protein according to any of the above 1 to 3, wherein the method comprises a step of conducting analysis employing (a) a nucleic acid encoding the polypeptide or protein and/or (b) the polypeptide or protein in a sample, as a marker.

15 19. The method of testing or diagnosing according to the above 18, which is a method of testing cancer cells or a method of diagnosing a cancer.

20. The method according to the above 18 or 19 which examines expression, increase, decrease, deletion or the like of all 20 or a part of the polypeptide or protein according to any of the above 1 to 3, wherein the method uses the antibody according to the above 11.

21. The method according to the above 18 or 19 which examines expression, mutation, deletion or insertion or the like of 25 all or a part of a gene encoding the polypeptide or protein according to any of the above 1 to 3 through a step of

amplifying a gene encoding the polypeptide or protein according to any of the above 1 to 3 using at least one of nucleic acid primers according to the above 10.

22. The method according to any of the above 18 to 21, wherein
5 the method combines examination of expression, increase,
decrease, mutation, deletion or insertion or the like of
all or a part of the tumor-suppressor gene retinoblastoma
gene (RB1 gene) or the gene product thereof (RB1 protein).
23. The method according to any of the above 18 to 22, wherein
10 the method combines examination of expression, increase,
decrease, mutation, deletion or insertion or the like of
all or a part of multidrug resistance gene (MDR1 gene) or
the gene product thereof (MDR1 protein: P-glycoprotein).
24. The method according to any of the above 18 to 23, wherein
15 the method combines examination of expression, increase,
or decrease or the like of all or a part of the cell
proliferation marker, Ki-67 protein.
25. A method that examines drug sensitivity of a cancer cell
using the method according to the above 23.
20 26. A reagent and a kit for assay or diagnosis, for use in
the method according to any of the above 18 to 25.

Brief Description of Drawings

Figure 1 shows photographs of Northern blots that
25 examined the relation between expression of human RB1CC1
gene and MDR1 gene.

Figure 2 shows a photograph of Western blots and of cellular immunostaining showing that human RB1CC1 protein is present in nucleus.

Figure 3 shows photographs of Western blots and of 5 cellular immunostaining showing that mouse Rb1cc1 protein is present in nucleus.

Figure 4 is a diagram that examined the effect on cell proliferation resulting from treatment with the anticancer agent doxorubicin.

10 Figure 5 shows photographs of Northern blots that examined the relation between cell proliferation caused by treatment with the anticancer agent doxorubicin and RB1CC1 gene expression and RB1 gene expression.

Figure 6 is a photograph of electrophoresis of RT-PCR 15 products that examined the relation between RB1CC1 gene expression and RB1 gene expression in various cancer cells.

Figure 7 shows photographs of Northern blots that examined the relation between RB1CC1 gene expression and RB1 gene expression in various human organs.

20 Figure 8 is a photograph of a Northern blot that examined the relation between RB1CC1 gene expression and RB1 gene expression in various mouse organs.

Figure 9 is a photograph of electrophoresis of RT-PCR 25 products that examined the effect on RB1 gene expression caused by introduction of RB1CC1 gene.

Figure 10 is a diagram showing results obtained after

testing the effect on transcriptional activity of RB1 gene promoter region caused by RB1CC1 gene induction.

Figure 11 is a photograph of results obtained after testing loss of heterozygosity of RB1CC1 gene locus in a
5 variety of primary breast cancers.

Figure 12 shows a photograph of electrophoresis of RT-PCR products that examined mutation of RB1CC1 gene in primary breast cancers, and a view showing the results of gene sequence analysis.

10 Figure 13 shows photographs of Western blots that examined expression of RB1CC1 protein and RB1 protein in primary breast cancers.

Figure 14 shows photographs of immunohistological staining that examined expression of RB1CC1 protein and RB1
15 protein in primary breast cancers.

Figure 15 shows diagrams illustrating the correlation between RB1CC1 as a stain indicator and Ki-67 and RB1.

Detailed Description of the Invention

20 (Novel protein RB1CC1)

The cDNA of the nucleic acid encoding the novel protein RB1CC1 provided according to the present invention was obtained by identifying a gene expressing differentially in U-2 OS osteosarcoma cells and MDR-variant induced cells,
25 conducting amplification employing U-2 OS mRNA as a template using nucleic acid primers described in SEQ ID Nos: 5 to

37 in the sequence listing, and determining the amino acid sequence coded for by cDNA of the novel protein and the base sequence, to thereby obtain the cDNA as a substance having a novel amino acid sequence. The cDNA of novel protein RB1CC1 5 of the present invention had a length of 6.6 kb, included an open reading frame (ORF) of 4782 nucleotides, and encoded a protein comprising 1594 amino acids with a molecular weight of 180 kDa.

The novel human protein RB1CC1 had a consensus nuclear 10 localization signal sequence site (lysine-proline-arginine-lysine sequence: KPRK), a leucine zipper motif sequence site, and a coiled-coil structure. It was suggested that the novel human protein RB1CC1 has DNA-binding and transcription functions.

15

(Novel mouse protein Rb1cc1)

Amplification was conducted employing mRNA of mouse muscle as a template using the nucleic acid primers described in SEQ ID Nos: 53 to 83 in the sequence listing, and the 20 amplification product was analyzed. The obtained cDNA coding for novel mouse protein Rb1cc1 had a chain length of 6518 bp with an open reading frame (ORF) of 4764 bp encoding 1588 amino acids. The novel mouse protein Rb1cc1 gene shared 89% homology with the novel human protein RB1CC1 gene. 25 Similarly to the human protein, novel mouse protein Rb1cc1 had a consensus nuclear localization signal sequence site

(lysine-proline-arginine-lysine sequence: KPRK), a leucine zipper motif sequence site, and a coiled-coil structure. It was suggested that mouse novel protein Rb1cc1 also has DNA-binding and transcription functions.

5

(Function of novel protein and gene)

To investigate the role of RB1CC1 gene of the present invention in MDR, RB1CC1 gene expression was compared for cases in which doxorubicin treatment was conducted for 10 parental U-2 OS cells, MDR variants of U-2 OS cells (U-2 OS/DX580), and U-2 OS cells introduced with MDR1 gene (U-2/DOXO35), whereby it was found that in the parental U2 OS cells and control cells introduced with a gene (U-2/Neo8) doxorubicin lowered expression of the RB1CC1 gene and induced 15 cell death. In contrast, in the MDR variants of U-2 OS cells, doxorubicin treatment did not exhibit an inhibitory effect on the expression level of RB1CC1 gene, cell lifetime, or cell proliferation, and in cells with the MDR1 gene the RB1CC1 gene expression was increased. In these cells, RB1CC1 gene 20 expression and RB1 gene expression correlated, and expression of both genes sustained the proliferation of these cells.

To examine the relation between expression of RB1 gene and the RB1CC1 gene of the present invention, expression 25 of both genes in 5 kinds of MDR-variants of U-2 OS human osteosarcoma cells and 24 kinds of human tumor cells (10

kinds of osteosarcoma, 4 kinds of lung cancer, 7 kinds of breast cancer, 3 kinds of blood cancer) was examined, whereby it was found that RB1CC1 gene expression strongly correlated with RB1 gene expression in all of the cells. Expression 5 of RB1CC1 gene and RB1 gene also showed a similar correlation in Northern blot analysis of nonneoplastic tissue.

Further, exogenous expression of the RB1CC1 gene of the present invention increased RB1 gene expression in K562 cells and Jurkat cells. Expression of MDR1 gene could not 10 be detected in these cells. Induction of RB1CC1 gene also stimulated transcriptional activity of RB1 gene promoter. Introduction of the RB1CC1 gene raised expression of RB1 gene through the stimulated activity of the RB1 gene promoter.

15 Considering the amino acid sequence of the novel protein RB1CC1, the nuclear locality thereof, and the expression pattern thereof, there is a possibility that the RB1CC1 gene of the present invention is a transcription factor that enhances RB1 gene expression directly or indirectly through a molecular intermediate. While analysis of promoter sequences of RB1 genes derived from human and mouse indicates the possibility of the presence 20 of a constitutive transcription factor such as Sp1 or ATF, a transcription factor that directly regulates RB1 gene expression is not known. In about 80% of human cancers, 25 molecules that are present in the RB1 gene pathway are

associated with the mechanism of carcinogenesis, and dysregulation of the RB1 gene plays an important role in the cancer of many people.

As shown in Table 1, human and mouse RB1CC1 genes of 5 the present invention both contain 24 exons and 23 introns, and length 74 kb or more and 57 kb or more in human and mouse, respectively. A translation initiation position is present at the site of exon 3. The structure of the gene in mouse was clarified using primers set forth in SEQ ID Nos: 84 to 10 132 of the sequence listing. When we investigated the localization sites of the gene on a chromosome, we found that the gene is present at 8q11.2 on the chromosome 8 in human and at 1A2-4 on the chromosome 1 in mouse.

Table1. Structure of RB1CC1 gene

No.	Exon		Intron		receptor sequence in splicing	donor sequence in splicing	Human Sequence
	No.	nucleic acid strand length (bp)	No.	nucleic acid strand length (kb)			
1	358	296	1	9.1	tcttttccas	TTCCTGAGT	GCGTTGCCGG gtaagtgtcg
2	115	110	2	1.3	tttcttctag	TAACCTGTATC	GTGCCTGACG gtaaagtcaaca
3	122	115	3	1.4	ttttttgaa	TGTGGCAGAC	CAGTGCAAAAC gtaaggtgta
4	127	127	4	0.2	aaaaatata	GATACAAAATC	TGCTGGGACG gtaggtattc
5	171	171	5	7.0	ttcaatata	GAAATGTATG	GCTTGCATTG gtaagatata
6	203	203	6	2.1	tttttttttt	AACTTACTCA	AACTTACTCA gtaatgttttc
7	430	427	7	5.7	gtattttaag	TTTAGGAAC	TATGAGCAGG gtaaagttaacg
8	171	171	8	8.3	tgtcatttag	CTTGATCCAA	GCTTGCTCAG gtaacctat
9	185	185	9	0.3	ttttctcaaa	GGATTTTTAG	TCAAGACTGAA gtaagtgatt
10	187	187	10	0.1	tatcttttca	TGGGTGTGTC	CTACAGGGAG gtaatcaast
11	82	82	11	0.3	cccttttttt	TGGGCTGGTG	AAATTATTTA gtaatgttgc
12	62	62	12	1.6	ctttatata	GGAAAGTCTT	TTCCCTTTTGT gtaatgtat
13	104	104	13	0.8	tttgatata	ACTCTAAAAGC	CATTCCCTCAG gtaaaatgtca
14	127	127	14	0.1	tctgttttca	GGTTCCCTTA	TGAACAAAAG gcaatttcaa
15	1801	1882	15	10.1	tgtttttccas	GCATCTGTGA	TAGCAAAAAG gtaagaat
16	166	166	16	2.9	aatttgtta	TCTTGCATT	GGAAACAACAG gtcgttatct
17	109	109	17	0.1	cttggttccas	ACCAATTTTA	CGGGATAAAAG gttttactg
18	241	241	18	6.3	tgtccttca	ATTTGATAGA	TGTCTGTACA gtaagtatgg
19	55	49	19	1.0	tcacttttat	AGAAAAATATT	GTAGAAACCA gtaagtaast
20	48	48	20	4.4	ccaccttgc	ACATTGCAAT	TCAAAAGACTG gtaagat
21	59	59	21	2.3	tttttttttt	ATGTCTCAGA	CTATTAGACA gtaagtat
22	137	137	22	3.5	cttiaattca	TTTTCAAGGTG	GCTGAGGGTG gtaatgtca
23	71	71	23	0.8	atttcattta	CTTCAGGTGC	AGCCAAAAAG gtaaaaacca
24	1401	1378			tccctttttt	GCACAAAAACA	

Exon sequences are shown in upper case letters,
and intron sequences are shown in lower case.

In order to detect mutations of RB1CC1 gene of the present invention, the RB1CC1 gene was analyzed using cDNA prepared from 35 cases of primary breast cancer, whereby 9 kinds of mutation were verified in 7 of cancers. There
5 were lacks at exons 3 to 24 in all of 9 kinds of mutation, and the fragmented novel protein RB1CC1 had lost its consensus nuclear localization signal sequence site, leucine zipper motif sequence site and coiled-coil structure, and did not have functions of the fundamental novel protein
10 RB1CC1.

Two of primary breast cancers (MMK 3 and 6) showed compound heterozygous lacks in both alleles, and it is predicted that a clearly fragmented novel protein RB1CC1 can be obtained from RB1CC1 gene with a lack. In MMK 6, there were lacks at exons 3 to 24 (nucleotides 534-5322) and exons 9 to 23 (nucleotides 1757-5187), with the respective frameshifting at codons 4 and 411. In MMK 3, there were lacks at exons 3 to 24 (nucleotides 535-5324) and exons 5 to 11 (nucleotides 849-2109), with termination occurring at codon 4 in the former, and a frame shift caused at codon 109 in the latter to result in obtainment of a protein fragment comprising 122 amino acids. Although irregular products corresponding to respective lack mutations were detected in PCR of genome DNA of cancer samples, mutations
20 were not observed in DNA of embryonic cells, revealing that these mutations occur in somatic cells. The novel protein
25

RB1CC1 was not detected in these cancers, and RB1 protein was absent in MMK 6 and was significantly less abundant than normal in MMK 3. There was no loss of heterozygosity at the RB1 loci on the chromosome in either case. In the cancer samples (MMK 12 and 29) without mutation of the RB1CC1 gene, both the novel protein RB1CC1 and RB1 protein were present. This suggests that inactivated mutation of the RB1CC1 gene causes RB1 gene expression to be insufficient and promotes dysregulation of the RB1 gene pathway, to cause canceration.

In other five breast cancers, (MMK 1, 15, 31, 38 and 40) also, lacks were detected in RB1CC1 gene that generated a protein fragment without function. These mutations were all heterozygotes, with loss of heterozygosity also present at the RB1CC1 loci, and since there was no expression of RB1CC1 gene in each of the cases, it was suggested that loss of function had occurred in both alleles. Expression of RB1 protein in these cancers was clearly reduced in comparison to cases (MMK 12 and 29) without mutation of RB1CC1 gene and RB1 gene. Loss of heterozygosity at the RB1 loci was not observed in these 5 cancers (MMK 1, 15, 31, 38, and 40).

Homozygous inactivation of the RB1CC1 gene of the present invention is associated with genesis of breast cancer. Lack mutations of the RB1CC1 gene that generated fragments of the novel protein RB1CC1 that clearly had no function were observed in approximately 20% of primary breast cancers

examined. Two of these cancers showed plural heterozygous lacks within the RB1CC1 gene, and the remainder showed loss of heterozygosity of the RB1CC1 gene. Although the novel protein RB1CC1 could not be detected in any of seven cancers, 5 protein was expressed in cancers without mutation of the RB1CC1 gene. Irrespective of the fact that there was no loss of heterozygosity at the RB1 loci, in all seven cancers the RB1 protein was either absent or significantly decreased.

The novel protein RB1CC1 performs regulation to 10 increase expression of the RB1 gene, and the RB1CC1 gene functions as a tumor suppressor in breast cancer. Further, abnormality or inactivation of the RB1CC1 gene leads to a decline in expression of RB1 gene, causing genesis and progression of cancer.

15 As described in the above-mentioned, since expression of the RB1CC1 gene and protein correlate with expression of RB1 gene, a more useful method of diagnosing cancer cells or cancer can be provided by performing tests that combine testing for the RB1CC1 gene and protein of the present 20 invention with testing for expression of the RB1 gene or expression of the protein.

Further, by also combining tests for multidrug resistance gene (MDR1) or the protein thereof, the effect of a pharmaceutical against a cancer or cancer cells can 25 be examined, enabling the provision of an examination method or a diagnostic method that is useful for selecting an

anticancer agent and predicting the effects thereof.

(Polypeptide or protein)

The novel protein of the present invention is a
5 polypeptide or protein comprising an amino acid sequence
represented by SEQ ID No: 1 or 2 in the sequence listing.
The polypeptide or protein of the present invention may also
be selected from polypeptides having a partial sequence of
the polypeptide represented by SEQ ID No: 1 or 2 in the sequence
10 listing. The selected polypeptide preferably has homology
of about 70% or more, more preferably about 80% or more,
and further preferably has homology exceeding about 90% with
the polypeptide represented by SEQ ID No: 1 or 2 in the sequence
listing. Selection of polypeptides having the homology can
15 be conducted, for example, by taking expression of RB1 gene
or RB1 protein as an indicator.

Techniques for determining homology of an amino acid
sequence are publicly known in the art and, for example,
a method that directly determines the amino acid sequence
20 or a method that first determines a putative base sequence
of a nucleic acid and then predicts the amino acid sequence
encoded by the base sequence may be used.

For the polypeptide of the present invention, an amino
acid sequence selected from polypeptides having a partial
25 sequence of a polypeptide or protein comprising an amino
acid sequence set forth in SEQ ID No: 1 or 2 in the sequence

listing can be utilized as a reagent, reference material or immunogen. The subject of the present invention is a polypeptide comprising, as a minimum unit thereof, the amino acid sequence composed of at least 5 amino acids, preferably 5 at least 8 to 10 amino acids or more, and more preferably at least 11 to 15 or more amino acids which can be screened immunologically.

Further, by employing expression of RB1 gene or RB1 protein as the indicator, there can also be provided a 10 polypeptide comprising an amino acid sequence having a mutation or induced mutation such as a deletion, substitution, addition or the like of one to several amino acids relative to the amino acid sequence of a polypeptide specified as described above. Methods for carrying out a deletion, 15 substitution, addition or insertion are publicly known, and, for example, the technique of Ulmer (Science, 219: 666, 1983) can be utilized. These available peptides can also be modified to a degree that is not accompanied by a noticeable change in function, such as modification of constitutive 20 amino groups or carboxyl groups or the like.

Polypeptides of the present invention can be used as they are in a pharmaceutical composition for regulating a function of the novel protein RB1CC1. Further, the polypeptide or protein of the present invention can be used 25 in screening to obtain a compound that can regulate a function of the novel protein RB1CC1, for example, an inhibitor,

antagonist, activator or the like, or an antibody against the novel protein RB1CC1. In addition, a polypeptide or protein of the present invention can also be used as a reagent or reference standard.

5

(Nucleic acid)

The term "nucleic acid and a complementary strand thereof" of the present invention refers to a nucleic acid set forth in SEQ ID No: 3 or 4 in the sequence listing that 10 codes for an amino acid sequence set forth in SEQ ID No: 1 or 2 in the sequence listing and the complementary strand for the nucleic acid, a nucleic acid hybridizing under stringent conditions with these nucleic acids, and a nucleic acid having a sequence of at least 15 consecutive base 15 sequence derived from these nucleic acids in which a peptide encoded thereby is capable of binding with an antibody against the novel protein RB1CC1. When DNA is taken as a typical example of the nucleic acid, the term "DNA hybridizing under stringent conditions to DNA" refers to 20 DNA that can be obtained by a publicly known method, for example, a method described in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989). Here the term "hybridizing under stringent conditions" refers to, for example, conditions under which 25 a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 × SSC, 0.5% SDS and 50%

formamide, and washing at 68 °C in a solution of 0.1 × SSC and 0.5% SDS.

The term "nucleic acid of the present invention" refers to a homologous strand and complementary strand selected from information of the nucleic acid set forth in SEQ ID No: 3 or 4 in the sequence listing that encodes an amino acid sequence described in SEQ ID No: 1 or 2 in the sequence listing, and also refers to a nucleic acid sequence comprising a sequence of at least about 15 to 20 nucleotides that correspond to a region of the specified nucleotide sequence, as well as the complementary strand thereof. Determination of this useful nucleic acid sequence can be conducted by simply confirming the expressed protein utilizing a publicly known protein expression system, for example, a cell-free protein expression system, and then screening by employing binding thereof with the antibody against bioactive novel protein RB1CC1 as the indicator. As the cell-free protein expression system, for example, a ribosome system derived from germ or rabbit reticulocyte or the like can be utilized (Nature, 179, 160-161, 1957).

Each of these nucleic acids provide genetic information that is useful for producing the novel protein RB1CC1 of the present invention and the polypeptide or protein of the present invention, and they can be used as primers or probes for detecting mRNA or a nucleic acid such as a gene encoding these, or as antisense oligomers to

regulate gene expression. Further, a nucleic acid of the present invention can also be utilized as a reagent or reference standard relating to the nucleic acid.

5 (Transformant)

In addition to the cell-free protein expression system described above, by employing genetic recombination techniques using a publicly known host such as *Escherichia coli*, yeast, *Bacillus subtilis*, an insect cell or animal 10 cell, it is possible to provide the novel protein RB1CC1 comprising the present invention and the polypeptide comprising a product derived therefrom.

Transformation can be conducted by applying publicly known means, for example, by transforming the host utilizing 15 a plasmid, chromosome, virus or the like as a replicon. As a more preferable system, a method that conducts integration into the chromosome may be mentioned when considering genetic stability. However, as a simple and convenient method, an autonomous replication system using an extranuclear gene 20 can be utilized. A vector can be selected according to the kind of host, and gene sequences that are objects of expression and gene sequences carrying information relating to replication and regulation can be employed as constituent elements. Constituent elements can be selected according 25 to whether the host is a prokaryotic cell or eukaryotic cell, and a promoter, ribosome binding site, terminator, signal

sequence, enhancer and the like can be combined according to a publicly known method and used.

The transformant can be used to produce the polypeptide of the present invention by culturing the transformant after 5 selecting optimal conditions from publicly known culture conditions for the respective hosts. While culturing may be conducted by employing as an indicator the physiological activity of the novel protein RB1CC1 to be expressed and produced and a polypeptide comprising the product derived 10 therefrom, in particular, RB1 gene inducing activity or DNA-binding transcription factor activity, it is generally conducted by subculture or batch culture employing the quantity of transformant in the medium as an indicator.

15 (Recovery of the novel protein RB1CC1 and product derived therefrom)

Recovery from the culture medium of the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom can be conducted by carrying out purification and 20 recovery that combines techniques such as a molecular sieving, an ion column chromatography, an affinity chromatography employing binding with the antibody against the novel protein RB1CC1 as the indicator, or by a fractionation technique using alcohol or ammonium sulfate or the like that is based 25 on difference in solubility.

(Antibody)

An antibody can be prepared by screening for an antigenic determinant of the novel protein RB1CC1 of the present invention and the polypeptide comprising the product derived therefrom. The antigenic determinant is composed of at least five amino acids, and more preferably at least 8 to 10 amino acids. The amino acid sequence need not necessarily be homologous with SEQ ID No: 1 or 2 in the sequence listing, and it is sufficient that the sequence is a site that is exposed to outside of the tertiary structure of the protein. If the exposed site is a discontinuous site, it is also effective that the amino acid sequence that is continuous with respect to the exposed site. The antibody is not particularly limited as long as it immunologically recognizes the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom. The presence or absence of the recognition can be determined by a publicly known antigen-antibody binding reaction.

Production of the antibody can be conducted by inducing immunity such as humoral response and/or cellular response in an animal using the novel protein RB1CC1 of the present invention and the polypeptide comprising the product derived therefrom by itself or in a state in which it is bonded with a carrier, in the presence or absence of an adjuvant. The carrier is not particularly limited as long as the carrier itself does not produce a deleterious effect on a host, and

examples thereof include cellulose, polymerized amino acid, and albumin. As an animal to be immunized, mouse, rat, rabbit, goat, horse or the like is preferable. A polyclonal antibody can be obtained by a publicly known method for recovering 5 antibody from serum.

Production of a monoclonal antibody can be carried out by recovering antibody-producing cells from the animal that has undergone the aforementioned immunization and introducing transformation means to publicly known 10 constantly proliferating cells.

The polyclonal or monoclonal antibody can be bonded directly with the novel protein RB1CC1 of the present invention to enable control of the activity thereof, and control of expression of the novel protein RB1CC1 and RB1 15 gene or protein can be easily performed. Therefore, the antibody is useful for treating or preventing a disease with which the RB1 gene product and the novel protein RB1CC1 are associated.

20 (Screening)

According to the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom that were prepared as described above, the nucleic acid encoding these and a complementary strand thereof, the cell 25 transformed based on information of these amino acid sequences and base sequences, and the antibody that

immunologically recognizes the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom, by use of a single means or by combining a plurality of means, there can be provided means effective in screening for binding with the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom, a function of the novel protein RB1CC1, or an inhibitor or activator of expression of the novel protein RB1CC1. More specifically, there can be provided a method of screening for compounds that inhibit or enhance expression of the polypeptide or protein and the RB1 gene or protein of the present invention by using at least one member of the group consisting of the polypeptide of the present invention and the antibody of the present invention. There can be provided a method of screening for compounds that interact with the nucleic acid of the present invention to inhibit or enhance expression of the nucleic acid by using at least one member of the group consisting of the nucleic acid of the present invention, vector of the present invention, transformant of the present invention, and antibody of the present invention. There can be provided a method of screening for compounds that inhibit or enhance a function of the polypeptide or protein of the present invention to regulate expression of the RB1 gene or protein by using at least one member of the group consisting of the polypeptide or protein of the present invention and the antibody of the present invention. For example,

screening for the antagonist obtained by drug design based on the tertiary structure of the polypeptide, screening for an expression regulator at the genetic level that utilizes a protein expression system, screening for an antibody 5 recognizing substance utilizing the antibody and the like can be utilized in a publicly known pharmaceutical screening system.

(Compound, pharmaceutical composition)

10 Compounds obtained by the above-described screening methods can be utilized as candidate compounds for the inhibitor, antagonist, activator or the like that regulates a function of the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom to control 15 expression of RB1 gene or protein. Compounds can also be utilized as candidate compounds for an inhibitor, antagonist, activator or the like for expression of the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom at the genetic level. Examples of aforementioned 20 candidate compounds for an inhibitor, antagonist, activator or the like include a protein, a polypeptide, a polypeptide without antigenicity, and a low molecular weight compound, and a low molecular weight compound is preferred.

Candidate compounds that were screened in the above 25 manner can be selected in consideration of a balance between biological usefulness and toxicity to be prepared as

pharmaceutical compositions to be used for treatment of osteosarcoma, leukemia or a tumor originating from the mammary gland, prostate gland, lung, or colon or the like. Further, the novel protein RB1CC1 comprising the present invention and the polypeptide comprising the product derived therefrom, nucleic acids encoding these and complementary strands thereof, vectors containing these base sequences, and antibodies that immunologically recognize the novel protein RB1CC1 and the polypeptide comprising the product derived therefrom can be used as pharmaceutical means, by themselves, that have an inhibitory, antagonizing or activating function with respect to interaction between the novel protein RB1CC1 and RB1 gene product and are used in treatment of breast cancer, prostate cancer and the like .

Here, the term "breast cancer, prostate cancer and the like" includes a benign tumor and a malignant tumor, and in this connection, at the time of formulation, publicly known formulation means may be introduced in accordance with the substance for formulation, such as the polypeptide, protein, nucleic acid or antibody.

The novel protein RB1CC1 of the present invention and the polypeptide comprising the product derived therefrom, nucleic acids encoding these and complementary strands thereof, vectors containing these base sequences, and antibodies that immunologically recognize the novel protein RB1CC1 and the polypeptide comprising the product derived

therefrom can be used as means for testing or diagnosing a disease with which expression of the polypeptide of the present invention or the activity thereof is related, such as a disease relating to expression of the novel protein RB1CC1 of the present invention or interaction with RB1 gene or the product thereof. In particular, they are useful as means for examination and diagnosis such as a diagnostic marker and/or reagent or the like for breast cancer, prostrate cancer and the like. Diagnosis can be conducted by utilizing interaction or reactivity with the nucleic acid sequence encoding the novel protein RB1CC1 to determine the abundance of a nucleic acid sequence of interest, and/or determine the biodistribution for the novel protein RB1CC1, and/or determine the abundance of the novel protein RB1CC1 in a test sample. More specifically, testing can be conducted utilizing the novel protein RB1CC1 as the diagnostic marker. As a method of determination, a publicly known antigen-antibody reaction system, enzyme reaction system, PCR reaction system or the like may be used. Further, a reagent kit or the like used in a method of examination and diagnosis is also included.

(Examples)

The present invention is described in further detail hereunder on the basis of examples, however, the present invention is not limited by the following examples.

(Example 1 cDNA of human RB1CC1)

In order to identify genes involved in MDR, we found a gene that expresses differentially in U-2 OS osteosarcoma cells and MDR-variant induced cells, to thereby identify a novel human gene. The gene was cloned using the set of primers (CC1-S1 and CC1-AS1) set forth in SEQ ID Nos: 5 and 26 and the set of primers (CC1-S2 and CC1-AS2) set forth in SEQ ID Nos: 6 and 25 in the sequence listing, and the nucleic acid sequence thereof was then determined using the primers set forth in SEQ ID Nos: 7 to 24. Further, the cDNA sequences at the 5'- and 3'-ends were identified using a commercially available rapid amplification kit for cDNA end sequences (RACE kit, manufactured by Roche) and the primers set forth in SEQ ID Nos: 27 to 37. The DNA and the amino acid sequence encoded thereby were analyzed using DNAsis Version 3.2 Sequence Analyzer (manufactured by Hitachi Software Engineering Co.) and PSORT II (<http://www.yk.rim.or.jp/~aisoai/molbio-j.html>).

Results showed that the cDNA had a length of 6.6 kb including an open reading frame (ORF) of 4782 nucleotides, encoding a protein comprising 1594 amino acids with a molecular weight of 180 kDa.

25 (Example 2 cDNA of mouse Rb1cc1)

The mRNA of mouse muscle was employed as a template

for amplification by RT-PCR, and cloning was then conducted using the set of primers (MCC1-S1 and MCC1-AS1) set forth in SEQ ID Nos: 53 and 73 and the set of primers (MCC1-S2 and MCC1-AS2) set forth in SEQ ID Nos: 54 and 72 in the sequence listing. The nucleic acid sequence was determined using primers set forth in SEQ ID Nos: 55 to 71 in the sequence listing. The cDNA of novel mouse protein Rb1cc1 was then identified using a similar method to Example 1, with the exception that rapid amplification of the cDNA was conducted using the primers (MCC-ASR1, MCC-ASR2, MCC-ASR3 and INTRON1ASR) set forth in SEQ ID Nos: 74 to 77 in the sequence listing as primers for the 5'-end RACE, and the primers (MCC-SR1, MCC-SR2, MCC3-S3, MCC3-S4, MCC3-AS2 and MCC3-AS3) set forth in SEQ ID Nos: 78 to 83 as primers for the 3'-end RACE. The cDNA encoding novel mouse protein Rb1cc1 has a strand length of 6518 bp including an open reading frame (ORF) of 4764 bp encoding 1588 amino acids. The gene of novel mouse protein Rb1cc1 had homology of 86% at the nucleic acid level and 89% at the protein level with the gene of novel human protein RB1CC1 (see SEQ ID Nos: 1 to 4).

(Example 3 Analysis of MDR1 gene and RB1CC1 gene of the present invention)

Expression levels of RB1CC1 gene and MDR1 gene in parental U2 OS cells and several kinds of MDR-variant cells were analyzed by Northern blotting. A probe hybridizing

between nucleotide numbers 4190 and 4654 of the RB1CC1 gene sequence was used as a probe for analysis of RB1CC1 gene, and a probe hybridizing between nucleotide numbers 834 and 1119 of MDR1 gene was used for MDR1 gene. Probes were used
5 after labeling with α -32P-dCTP in which phosphorus at an alpha position of deoxycytidine-3-phosphate was substituted with a radioactive isotope. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the indicator of mRNA expression. The results showed
10 that the expression levels of both genes correlated inversely (Figure 1).

(Example 4 Preparation of antibody and Western blot analysis)

15 Three kinds of synthetic polypeptide were prepared which respectively comprised amino acids 642 to 658 (RB1CC-642), 744 to 757 (RB1CC-744) and 1104 to 1118 (RB1CC-1104) of the amino acid sequence of the novel protein RB1CC1 of the present invention. Rabbits were immunized
20 by a conventional method with substances in which a cysteine residue had been introduced at the amino terminus of each polypeptide, and antibody was then obtained. After subjecting nuclear components and cytoplasmic components of U-2 OS cells to SDS-PAGE, respectively, analysis was
25 carried out by Western blotting using the antibody prepared above. Results showed that RB1CC1 protein of a molecular

weight of 180 kDa was present in the nucleus (Figure 2).

After subjecting nuclear components and cytoplasmic components of NIH3T3-3 cells of mouse to electrophoresis in a similar manner, Western blot analysis was conducted 5 using the RB1CC-642 antibody. Detection of stathmin was simultaneously conducted using anti-stathmin rabbit antibody. Results showed that the Rblcc1 protein is localized in the nucleus, while stathmin is present in cytoplasm. When same cells were subjected to 10 immunocytochemical staining using each antibody and then compared, it was found that while the nucleus was stained with the RB1CC-642 antibody, the cytoplasm was stained with the anti-stathmin rabbit antibody (Figure 3).

Above results showed that the novel protein RB1CC1 15 of the present invention is present in the nucleus of mammalian cells.

(Example 5 Effect of anticancer agent on expression of RB1CC1 gene of the present invention)

20 The influence of an anticancer agent was assessed for 4 kinds of cells that were treated with doxorubicin, including parent cells (U-2 OS), MDR variants of U-2 OS cells (U-2 OS/DX580) and U-2 OS cells introduced with the MDR1 gene (U-2/DOXO 35). The effect on cell proliferation in 25 the presence of 450 ng/mL of the anticancer agent doxorubicin was examined. As shown in Figure 4, results indicated that

while cell proliferation was suppressed by the anticancer agent in parental U2 OS cells and control cells introduced with a gene (U-2/Neo8), the anticancer agent had no effect on MDR variants of U-2 OS cells (U-2 OS/DX580) and U-2 OS cells introduced with MDR1 gene (U-2/DOXO 35) and cell proliferation continued for 120 hours or more (Figure 4).

mRNA expression levels of cells that were obtained over time in the above-mentioned experiment were analyzed. Analysis was conducted for the novel gene RB1CC1 gene of the present invention, the RB1 gene and the MDR1 gene, respectively, in the same manner as Example 3 with the exception that expression levels of the RB1 gene were detected using a probe hybridizing to the site at nucleotides 336 to 675 of the nucleotide sequence of human RB1 mRNA. Results are shown in Figure 5. For parental U2 OS cells and control cells introduced with a gene (U-2/Neo8) for which the effect of the anticancer agent was observed, expression of the RB1CC1 gene decreased over time. In contrast, in MDR variants of U-2 OS cells (U-2 OS/DX580) and U-2 OS cells introduced with MDR1 gene (U-2/DOXO 35), expression level of RB1CC1 gene was not inhibited by treatment with doxorubicin, and expression of RB1CC1 gene increased. In these cells, RB1CC1 gene expression and RB1 gene expression correlated (Figure 5).

25

(Example 6 Expression of RB1 gene and RB1CC1 gene of the

present invention)

The expression of RB1CC1 gene and RB1 gene in various cancer cells was assessed by semi-quantitative RT-PCR. Cell lines used were SARG, IOR/OS9, 10, 14, 15, 18, MOS (these 5 were obtained from surgical samples of advanced human osteosarcoma), Saos-2, HOS, MCF-7, T-47D, BT-20, SK-BR3, ZR75-1, MDA-MB-231, Daudi, Jurkat and K562 (these were purchased from the American Type Culture Collection), NZK-K1 (this was established from breast cancer tissue of a 46-year 10 old female), LK2, QG56, EBC1 and SBC2 (these were provided by Doctor Tatsuhiko Narita of Aichi Cancer Center). 2 µg of RNA was extracted from each cell line, and subjected to 22 to 30 cycles of RT-PCR for amplification. Publicly known primers were synthesized and used as primers for the RB1 15 gene (Sauerbrey et al., 1996). The combination of primers set forth in SEQ ID Nos: 19 and 20 in the sequence listing (CC1-S and CC1-AS) were used as primers for amplification of RB1CC1. β_2 -microglobulin was used as a control. In all of these cells, expression of RB1CC1 gene correlated closely 20 with that of RB1 gene. Figure 6 shows results for one case of normal leukocyte and six cancer cells: T-47D, MCF7, NZK-K1, Daudi, K562 and Jurkat (Figure 6).

(Example 7 Expression of RB1CC1 gene and RB1 gene of the 25 present invention in organs)

Northern blot analysis was conducted for RB1CC1 gene

and RB1 gene expressing in nonneoplastic tissue of human brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung and leukocyte, respectively, using commercially available MTN Blots (manufactured by Clontech). Results are shown in Figure 7. Both genes were expressed strongly in heart and skeletal muscle, while expression was weak in colon, small intestine, lung and leukocyte. However, expression of RB1CC1 gene and RB1 gene correlated. Northern blot analysis was also conducted for Rb1cc1 gene expressing in respective tissues of heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis of mouse. Results are shown in Figure 8. Transcription products of 6.2 kb and 6.8 kb were expressed strongly in heart, while expression was observed to a certain extent in kidney, liver and skeletal muscle. The principal expression in testis was 6.2 kb, while expression was weak in lung and spleen (Figure 7, Figure 8).

(Example 8 Expression of RB1 gene induced by introduction of RB1CC1 gene of the present invention)

Jurkat and K562 cells that had weak expression levels for both RB1CC1 gene and RB1 gene among cells shown in Example 6 were subjected to exogenous introduction of RB1CC1 gene to examine changes in the expression of RB1 gene. A 4.9-kb gene that included the complete coding region of the RB1CC1 molecule was incorporated into pCR3.1-Uni vector

(manufactured by Invitrogen), which was then cloned to prepare an RB1CC1 expression vector (pCR-RB1CC). The thus-prepared expression vector was incorporated into K562 and Jurkat cells to prepare RB1CC1 transformed cells. A 5 control was prepared by incorporating lac Z gene into pCR3.1-Uni vector. Respective expression levels of RB1CC1 gene and RB1 gene in parent cells and transformed cells (cells introduced with RB1CC1 gene) were examined in a similar manner to Example 6. Figure 9 shows the results. Although 10 expression of both RB1CC1 gene and RB1 gene was weak in untransformed cells and cells into which the lac Z gene was incorporated, it was found that in cells incorporated with RB1CC1 gene, the RB1CC1 gene expression was strong as expected and the RB1 gene was also strongly expressed, 15 showing that expression of the RB1 gene was also induced by introduction (exogenous expression) of the RB1CC1 gene (Figure 9).

(Example 9 RB1 gene promoter transcriptional activity of 20 RB1CC1 gene of the present invention)

We examined whether introduction of the RB1CC1 gene enhanced the transcriptional activity of the promoter region of RB1 gene. A gene of RB1 promoter region of approximately 2 kb was amplified with the pair of primers 5'-GAA GAT CTT 25 TGA AAT TCC TCC TGC ACC A-3' (Bgl.RbPro-S) and 5'-CCC AAG CTT AGC CAG CGA GCT GTG GAG-3' (Hind.RbPro-AS), and

incorporated into PicaGene Basic vector 2 (manufactured by Toyō Ink Mfg. Co., Ltd.). Then, RB1 promoter which controls expression of firefly luciferase was used to prepare pGV-RbPro vector. The prepared pGV-RbPro vector was then 5 retranscribed with pRL-SV40 encoding the sea pansy luciferase gene, as an internal control, and incorporated into K562 cell using LIPOFECTAMINE PLUS reagent (manufactured by GIBCO-BRL). Results of analysis conducted after 48 hours using a double luciferase assay system (Toyo 10 Ink Mfg. Co., Ltd.) showed that K562 cell introduced with RB1CC1 gene exhibited strong luciferase activity compared to K562 cell incorporated with lac Z as a control, showing that introduction of the RB1CC1 gene enhanced the transcriptional activity of RB1 gene promoter (Figure 10).

15

(Example 10 Loss of heterozygosity at locus (D8S567) of RB1CC1 gene in primary breast cancer)

DNA samples of cancer tissue and genome DNA from same patients were amplified by PCR and the amplification products 20 were analyzed using 8% urea-denatured polyacrylamide gel electrophoresis. Results obtained by silver staining after electrophoresis are shown in Figure 11. While two bands were observed for the genome DNA of each patient to indicate retention of heterozygosity, only one band was detected in 25 five cases of DNA of cancer tissue, indicating loss of heterozygosity (Figure 11).

(Example 11 Analysis of mutation of RB1CC1 gene of the present invention in breast cancer)

Mutations of RB1CC1 gene were identified by analyzing 5 the genetic sequence of cDNA samples that were amplified using ELONGASE System (manufactured by GIBCO-BRL) with the pair of primers (CC1-S2 and CC1-AS2) set forth in SEQ ID Nos: 6 and 25 that were used in Example 1, using ABI PRISM 310 genetic analyzer and the primers set forth in SEQ ID 10 Nos: 7 to 24 in the sequence listing. As a result, 7 cases of mutation were verified among 35 cases of breast cancer, and 9 kinds of variants were verified. This result was reconfirmed using primers set forth in SEQ ID Nos: 38 to 52. Results are shown in Table 2.

Table 2. Mutations of RB1CC1 gene in primary breast cancer

sample name	nucleotide mutation	location (exon)	predicted influence	genome DNA	State of RB1CC1 gene		State of RB1	
					allele	protein	LOH	protein
MMK3	c.11_4800del c.325_1585del	3-24 5-11	Y41fsX4 P109fsX122	wild type	plural heterozygous deletions	(-)	(-)	↓↓
MMK6	c.10_4798del c.1233_4533del	3-24 9-23	Y41fsX48 D411fsX481	wild type	plural heterozygous deletions	(-)	(-)	(-)
MMK1	c.957_4785del	7-24	N319fsX368	wild type	plural heterozygous deletions	(-)	(-)	↓↓
MMK15	c.1635_4719del	12-24	S545fsX557	wild type	plural heterozygous deletions	(-)	(-)	(-)
MMK31	c.212_4188del	5-24	I71fsX111	wild type	plural heterozygous deletions	(-)	(-)	(-)
MMK38	c.241_4621del	5-22	C81fsX99	wild type	plural heterozygous deletions	(-)	(-)	↓↓
MMK40	c.591_4678del	7-23	S197fsX212	wild type	plural heterozygous deletions	(-)	(-)	↓↓

(-): absent, ↓↓: significantly decreased
LOH: loss of heterozygosity

(Example 12)

Figure 12 shows results of analysis of PCR products for MMK6 in which mutation was observed in RB1CC1 gene and

MMK29 in which mutation was not observed among samples analyzed in Example 11, as well as the results of genetic sequence analysis corresponding thereto. It was found that a gene of 4.9 kb expressed in MMK29 that was without mutation,
5 while the 4.9-kb expression was not observed in MMK6 with mutation and expression of gene fragments (1456 bp and 98 bp) was observed (Figure 12).

(Example 13 Analysis by Western blotting)

10 From the samples analyzed in Example 11, expression of the novel protein RB1CC1 and the RB1 protein was verified by Western blotting in 3 cancers (MMK6, MMK40, MMK38) in which mutation was observed in RB1CC1 gene and 2 cancers (MMK12, MMK29) in which mutation was not observed. After
15 subjecting extracted protein to 5% SDS-polyacrylamide gel electrophoresis, and then transferring to PVDF membrane, reaction was conducted with the anti-human RB1CC1 antiserum (α -RB1CC-642) prepared in Example 4. The RB1 protein was reacted with RB1 monoclonal antibody (G3-245, manufactured
20 by PharMingen Inc.). After reaction, detection was carried out using ECL reagent (manufactured by Amersham Biosciences). The results are shown in Figure 13. While novel protein RB1CC1 having a molecular weight of 180 kDa and RB1 protein of a molecular weight of 110 to 116 kDa both expressed in
25 MMK12 and MMK29 without mutation, in contrast, expression of either protein was not observed in any of 3 cancers with

a mutation (Figure 13).

(Example 14 Immunohistological staining)

Immunohistological staining was conducted for 2 cancers (MMK3, MMK6) in which mutation in RB1CC1 gene was observed and 1 cancer (MMK 12) in which mutation was not observed among samples analyzed in Example 11. The antibody used for reaction was the same as that in Example 13, and the antibody was reacted with tissue sections prepared from paraffin blocks obtained from each of cancer samples. As shown in Figure 14, the expression levels of novel protein RB1CC1 and RB1 protein correlated, and it was verified that expression levels were clearly lower in 2 cancers (MMK3, MMK6) in which mutation in RB1CC1 gene was observed compared to the cancer (MMK 12) in which mutation was not observed (Figure 14).

(Example 15)

54 samples of primary breast cancer tissue were assayed by immunohistological staining in a similar manner to Example 14, and the RB1CC1 protein was not detected in 8 samples (corresponding to 15%). Then, RB1 protein expression was absent or significantly lowered in all of the samples.

For 46 cases expressing RB1CC1 protein, the RB1 protein was simultaneously expressed in 45 cases. When the RB1 protein expression was compared with the RB1CC1 positive

group and negative group by stain indication using immunohistological staining (indication showing as a percentage the ratio of the number of cells stained among 1000 or more cells), the RB1CC1 positive group and negative group were found to show a positive correlation with RB1CC1 expression, with $78.6 \pm 13.9\%$ and $13.6 \pm 12.1\%$, respectively (Figure 15a). Meanwhile, when immunohistological staining for Ki-67 was conducted using mouse monoclonal antibody (NCL-Ki-67-MMI, manufactured by Novocastra Inc.), the stain indication was $20.3 \pm 12.8\%$ for the RB1CC1 positive group and $65.0 \pm 12.2\%$ for the negative group, showing a clearly inverse correlation with RB1CC1 expression (Figure 15b).

These results indicate that in cancers in which expression of RB1CC1 protein is suppressed, the cell proliferation marker Ki-67 is expressed in large amounts, and proliferation of cancer cells flourishes. It was thus found that assaying using a combination of RB1CC1 protein and Ki-67 is useful for cancer diagnosis.

By testing for the novel gene (RB1CC1 gene) of the present invention and the protein (RB1CC1) thereof, information that is useful for the diagnosis of cancer cell proliferation and cancer can be provided.

Claims

1. A protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof.
2. The human protein according to claim 1, which is a polypeptide or protein selected from a group consisting of:
 - 10 (1) a polypeptide or protein represented by an amino acid sequence set forth in SEQ ID No: 1 in the sequence listing;
 - (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology of at least approximately 70% at the amino acid sequence level with the polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).
- 25 3. The animal protein according to claim 1 that is a protein derived from mouse, and which is a polypeptide or protein selected from the group consisting of: (1) a polypeptide or protein represented by an amino acid sequence set forth

in SEQ ID No: 2 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology 5 of at least approximately 70% at the amino acid sequence level with the polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the 10 polypeptide or protein according to any one of the preceding (1) to (3).

4. A nucleic acid coding for the polypeptide or protein according to any one of claims 1 to 3, or a complementary 15 strand thereof.

5. A nucleic acid hybridizing under stringent conditions with the nucleic acid according to claim 3 or the complementary strand thereof.

20

6. A nucleic acid represented by a base sequence comprising at least 15 consecutive bases of the base sequence of a nucleic acid set forth in SEQ ID Nos: 3 to 4 in the sequence listing or a complementary strand thereof, wherein a polypeptide 25 expressed by transcription of the nucleic acid is the polypeptide according to any one of claims 1 to 3.

7. A recombinant vector containing the nucleic acid according to any one of claims 4 to 6.

5 8. A transformant that was transformed with the recombinant vector according to claim 7.

9. A method for producing the polypeptide or protein according to any one of claims 1 to 3, comprising a step
10 of culturing the transformant according to claim 8.

10. Nucleic acid primers set forth in SEQ ID Nos: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid according to any one of
15 claims 4 to 6 or the complementary strand thereof.

11. An antibody that immunologically recognizes the polypeptide or protein according to any one of claims 1 to 3.

20

12. A method of screening for compounds that inhibit or enhance a function that can induce transcription factor activity and/or expression of RB1 gene of the polypeptide or protein according to any of claims 1 to 3, wherein the
25 method uses at least one member of the group consisting of the polypeptide or protein according to any one of claims

1 to 3 and the antibody according to claim 11.

13. A method of screening for compounds that interact with
the nucleic acid according to claim 4 or 6 to inhibit or
5 enhance expression of the nucleic acid, wherein the method
uses at least one member of the group consisting of the nucleic
acid according to any one claims 4 to 6, the vector according
to claim 7, the transformant according to claim 8, and the
nucleic acid primers according to claim 10.

10

14. A compound that was screened by the screening method
according to claim 12 or 13.

15. A compound that inhibits or enhances transcription factor
activity and/or a function that can induce expression of
RB1 gene of the polypeptide or protein according to any of
claims 1 to 3.

16. A compound that interacts with the nucleic acid according
20 to any one of claims 4 to 6 to inhibit or enhance expression
of the nucleic acid.

17. A pharmaceutical composition for use in treatment of
multidrug resistance that is resistance to treatment with
25 anticancer agents, wherein the pharmaceutical composition
comprises at least one member of the group consisting of

the polypeptide or protein according to any of claims 1 to 3, the nucleic acid according to any one of claims 4 to 6, the vector according to claim 7, the transformant according to claim 8, the nucleic acid primers according to claim 10, 5 the antibody according to claim 11, and the compound according to any one of claims 14 to 16.

18. A method of testing and diagnosing a disease related with expression or activity of the polypeptide or protein 10 according to any of claims 1 to 3, wherein the method comprises a step of conducting analysis employing (a) a nucleic acid encoding the polypeptide or protein and/or (b) the polypeptide or protein, as a marker in a sample.

15 19. The method of testing and diagnosing according to claim 18, which is a method of testing cancer cells or a method for diagnosing a cancer.

20. The method according to claim 18 or 19 which detects expression, increase, decrease, lack or the like of all or a part of the polypeptide or protein according to any of claims 1 to 3, wherein the method uses the antibody according to claim 11.

25 21. The method according to claim 18 or 19 which detects expression, mutation, lack or insertion or the like of all

or a part of a gene encoding the polypeptide or protein according to any of claims 1 to 3 through a step of amplifying a gene encoding the polypeptide or protein according to any of claims 1 to 3 using at least one of nucleic acid primers 5 according to claim 10.

22. The method according to any of claims 18 to 21, wherein the method combines assay of expression, increase, decrease, mutation, lack or insertion or the like of all or a part 10 of tumor-suppressor gene retinoblastoma gene (RB1 gene) or the gene product thereof (RB1 protein).

23. The method according to any of claims 18 to 22, wherein the method combines assay of expression, increase, decrease, 15 mutation, lack or insertion or the like of all or a part of multidrug resistance gene (MDR1 gene) or the gene product thereof (MDR1 protein: P-glycoprotein).

24. The method according to any of claims 18 to 23, wherein 20 the method combines assay of expression, increase, or decrease or the like of all or a part of the cell proliferation marker, Ki-67 protein.

25. A method that tests drug sensitivity of a cancer cell 25 using the method according to claim 23.


26. A kit and a reagent for assay or diagnosis, for use in
the method according to any of claim 18 to 25.

ABSTRACT

To provide a novel gene and protein involved in multidrug resistance in cancer, to elucidate functions of 5 the gene and protein, to provide methods of detecting the gene and antibody against the protein and of testing and diagnosing cancer using the gene and antibody, we found a novel protein (RB1CC1) or polypeptide and gene thereof present in nucleus of human or animal cells and having 10 transcription factor functions and/or functions inducing expression of retinoblastoma-1 gene (RB1 gene) or the gene product. We determined the amino acid sequence and cDNA sequence, conducted gene amplification and detection with primers hybridizing with the gene, tested for expression 15 and mutation of the gene, discovered the gene relates to cancer cell proliferation and assayed cancers, prepared antibody against the protein and detected the protein using the antibody, whereby we found a relation between the protein and cancer cell proliferation, and assayed cancers.

Drawings

Fig. 1



BEST AVAILABLE COPY

Fig. 2

RB1CC1
(180 kDa)

Cytoplasm

Nucleus






Fig. 3

Rb1cc1
(180 kDa)

Stathmin
(18 kDa)



Rb1cc1 Stathmin

Fig. 4




Fig. 5





Fig. 6

RB1CC1
RB1
B2-MG




Fig. 7




Fig. 8






Fig. 9

RB1CC1
RB1
B2-MG



Jurkat.RB1CC-1

Jurkat

K562.RB1CC-2

K562.RB1CC-1

K562.lacZ

K562

Fig. 10




Fig. 11




Fig. 12




Fig. 13

RB1CC1
(180 kDa)

RB1
(~110-116 kDa)




Fig. 14





Fig. 15



10/516558

Docket No. 3190-070

Kilyk & Bowersox, P.L.L.C.

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状 Japanese Language Declaration 日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する： As a below named inventor, I hereby declare that:

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。 My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初で、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

the specification of which is attached hereto unless the following box is checked:

_____ の日に出願され、
この出願の米国出願番号または PCT 国際出願番号は、
_____ であり、且つ
_____ の日に補正された出願（該当する場合）

was filed on January 30, 2003
as United States Application Number or
PCT International Application Number
PCT/JP03/00882 and was amended on
(if applicable).
(now assigned U.S. Patent
Application No. 10/516,558)

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第 37 編規則 1. 56 に定義されている、特許性について重要な情報を開示する義務があることを承認する。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

COPY

Docket No. 3190-070

Kilk & Bowersox, P.L.L.C.

Japanese Language Declaration

日本語宣言書

私は、ここに、以下に記載した外国での特許出願または発明者証出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)(b)項又は第365条(b)項に基づいて優先権の利益を主張するとともに、優先権を主張する本出願の出願日よりも前の出願日を有する外国で特許出願または発明者証出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

Prior Foreign Application(s)

外国での先行出願

JP2002-161400
(Number)
(番号)

Japan
(Country)
(国名)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed.

Priority Claimed	YES	NO
優先権主張	あり <input checked="" type="checkbox"/>	なし <input type="checkbox"/>

JP2002-214978
(Number)
(番号)

Japan
(Country)
(国名)

03/06/2002
(Day/Month/Year Filed)
(出願日／月／年)

他の優先権出願については添付のリスト参照

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編119条(e)項の利益を主張する。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関する重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(現況 : 特許許可、係属中、放棄)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

(Status: Patented, Pending, Abandoned)
(現況 : 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第108編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COPY

Docket No. 3190-070

Kilyk & Bowersox, P.L.L.C.

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状 Japanese Language Declaration 日本語宣言書

委任状： 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び／または弁理士を任命する。

POWER OF ATTORNEY: As a named inventor, I hereby appoint The following attorney(s) and/or agent(s) to prosecute this Application and transact all business in the Patent and Trademark Office connected therewith.

33432
米国特許商標庁

全ての通信は下記の住所へ送付されたい。

Kilyk & Bowersox P.L.L.C.
53 リーの東の通り
Warrenton の VA 20186

33432
PATENT TRADEMARK OFFICE


Please direct all communications to the following address:

KILYK & BOWERSOX, PLLC
53 A East Lee Street
Warrenton, VA 20186
(Tel) 540-428-1701

唯一または第一発明者氏名

発明者の署名 日付

Full name of sole or first inventor
Tokuhiro CHANO

Signature 

Date 04 Dec 13

住所

Residence
9-34-809, Nomura 5-chome, Kusatsu-shi, Shiga 525-0027 Japan

国籍

Citizenship

Japanese

郵便の宛先

Post Office Address

Same as above

第二共同発明者がいる場合、その氏名

発明者の署名 日付

Full name of second joint inventor, if any
Hidetoshi OKABE

Signature 

Date 04 Dec 13

住所

Residence
101-5, Momoyamaminamioshima-cho, Fushimi-ku,
Kyoto-shi, Kyoto 612-8017 Japan

Citizenship

Japanese


Post Office Address

Same as above

第三共同発明者がいる場合、その氏名

発明者の署名 日付

Full name of third joint inventor, if any
Shiro IKEGAWA

Signature 

Date 04 Dec 13

住所

Residence
12-22-201, Kamiosaki 1-chome, Shinagawa-ku,
Tokyo 141-0021 Japan

Citizenship

Japanese

Post Office Address

Same as above

Date: January 25, 2005 Label No. EV567259572US I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Chano et al.)	Examiner:	Unassigned
)		
Application No.:	10/516,558)	Group Art Unit:	Unassigned
)		
Filed:	November 30, 2004)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-070)	Customer No.:	33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

PRELIMINARY AMENDMENT

COPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 25, 2005

Sir:

Prior to examination of the above-identified application on the merits, applicants respectfully request that the application be amended as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 9 of this paper.

Preliminary Amendment
U.S. Patent Application No. 10/516,558

COPY

Amendments to the Specification:

On page 1, after the title, please insert the following paragraph:

This application is a National Stage Application of PCT/JP03/00882, filed January 30, 2003.

COPY

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof.
2. (original) The human protein according to claim 1, which is a polypeptide or protein selected from a group consisting of: (1) a polypeptide or protein represented by an amino acid sequence set forth in SEQ ID No: 1 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology of at least approximately 70% at the amino acid sequence level with the polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).
3. (original) The animal protein according to claim 1 that is a protein derived from mouse, and which is a polypeptide or protein selected from the group consisting of: (1) a polypeptide or protein represented by an amino acid sequence set forth in SEQ ID No: 2 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology

COPY

Preliminary Amendment
U.S. Patent Application No. 10/516,558

of at least approximately 70% at the amino acid sequence level with the polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).

4. (currently amended) A nucleic acid coding for the polypeptide or protein according to ~~any one of claims 1 to 3~~ claim 1, or a complementary strand thereof.

5. (original) A nucleic acid hybridizing under stringent conditions with the nucleic acid according to claim 3 or the complementary strand thereof.

6. (currently amended) A nucleic acid represented by a base sequence comprising at least 15 consecutive bases of the base sequence of a nucleic acid set forth in SEQ ID Nos: 3 to 4 in the sequence listing or a complementary strand thereof, wherein a polypeptide expressed by transcription of the nucleic acid is the polypeptide according to ~~any one of claims 1 to 3~~ claim 1.

7. (currently amended) A recombinant vector containing the nucleic acid according to ~~any one of claims 4 to 6~~ claim 4.

8. (original) A transformant that was transformed with the recombinant vector according to claim 7.

Preliminary Amendment

U.S. Patent Application No. 10/516,558

9. (currently amended) A method for producing the polypeptide or protein according to any one of claims 1 to 3 claim 1, comprising a step of culturing the transformant with the recombinant vector containing nucleic acid coding for the polypeptide or protein according to claim 8.

10. (currently amended) Nucleic acid primers set forth in SEQ ID Nos: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid according to any one of claims 4 to 6 claim 4 or the complementary strand thereof.

11. (currently amended) An antibody that immunologically recognizes the polypeptide or protein according to any one of claims 1 to 3 claim 1.

12. (currently amended) A method of screening for compounds that inhibit or enhance a function that can induce transcription factor activity and/or expression of RB1 gene of the polypeptide or protein according to any of claims 1 to 3 claim 1, wherein the method utilizes uses at least one member of the group consisting of the polypeptide, or the protein, or an antibody that immunologically recognizes the polypeptide or protein according to any one of claims 1 to 3 and the antibody according to claim 11.

13. (currently amended) A method of screening for compounds that interact with the nucleic acid according to claim 4 or 6 to inhibit or enhance expression of the nucleic acid, wherein the method utilizes uses at least one member of the group consisting of the nucleic acid according to any one of claims 4 to 6, the, a recombinant vector containing the nucleic acid according to claim 7,

COPY

Preliminary Amendment

U.S. Patent Application No. 10/516,558

the, a transformant that was transformed with the recombinant vector according to claim 8, and
the or nucleic acid primers set forth in SEQ ID NOS: 5 to 132 in the sequence listing which
hybridize under stringent conditions with the nucleic acid according to claim 10.

14. (currently amended) A compound that was screened by the screening method according to claim 12-~~or~~13.

15. (currently amended) A compound that inhibits or enhances transcription factor activity and/or a function that can induce expression of RB1 gene of the polypeptide or protein according to ~~any of claims 1 to 3~~ claim 1.

16. (currently amended) A compound that interacts with the nucleic acid according to ~~any one of claims 4 to 6~~ claim 4 to inhibit or enhance expression of the nucleic acid.

17. (currently amended) A pharmaceutical composition for use in treatment of multidrug resistance that is resistance to treatment with anticancer agents, wherein the pharmaceutical composition comprises ~~at least one member of the group consisting of~~ the polypeptide or protein according to ~~any of claims 1 to 3~~ claim 1, ~~the, a nucleic acid coding for the polypeptide or protein or a complementary strand thereof according to any one of claims 4 to 6, the, a recombinant vector containing the nucleic acid according to claim 7, the, a transformant that was transformed with the recombinant vector according to claim 8, the, nucleic acid primers set forth in SEQ ID NOS: 5 to 132 in the sequence listing which hybridize under stringent conditions with the nucleic acid according to claim 10, the, an antibody that immunologically recognizes the polypeptide or~~

COPY

protein according to claim 11, and the or a compound that interacts with nucleic acid to inhibit or enhance expression of the nucleic acid according to any one of claims 14 to 16.

18. (currently amended) A method of testing and diagnosing a disease related with expression or activity of the polypeptide or protein according to any of claims 1 to 3 claim 1, wherein the method comprises a step of conducting analysis employing (a) a nucleic acid encoding the polypeptide or protein and/or (b) the polypeptide or protein, as a marker in a sample.

19. (original) The method of testing and diagnosing according to claim 18, which is a method of testing cancer cells or a method for diagnosing a cancer.

20. (currently amended) The method according to claim 18 ~~or 19~~ which detects expression, increase, decrease, lack or the like of all or a part of the polypeptide or protein according to any of claims 1 to 3, wherein the method utilizes ~~uses the~~ an antibody that immunologically recognizes the polypeptide according to claim 11.

21. (currently amended) The method according to claim 18 ~~or 19~~ which detects expression, mutation, lack or insertion or the like of all or a part of a gene encoding the polypeptide or protein according to any of claims 1 to 3 through a step of amplifying a gene encoding the polypeptide or protein according to any of claims 1 to 3 utilizing at least one of nucleic acid primers set forth in SEQ ID NOS: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid according to claim 10.

COPY

Preliminary Amendment
U.S. Patent Application No. 10/516,558

22. (currently amended) The method according to ~~any of claims 18 to 21~~ claim 18, wherein the method combines assay of expression, increase, decrease, mutation, lack or insertion or the like of all or a part of tumor-suppressor gene retinoblastoma gene (RB1 gene) or the gene product thereof (RB1 protein).

23. (currently amended) The method according to ~~any of claims 18 to 22~~ claim 18, wherein the method combines assay of expression, increase, decrease, mutation, lack or insertion or the like of all or a part of multidrug resistance gene (MDR1 gene) or the gene product thereof (MDR1 protein: P-glycoprotein).

24. (currently amended) The method according to ~~any of claims 18 to 23~~ claim 18, wherein the method combines assay of expression, increase, or decrease or the like of all or a part of the cell proliferation marker, Ki-67 protein.

25. (original) A method that tests drug sensitivity of a cancer cell using the method according to claim 23.

26. (currently amended) A kit and a reagent for assay or diagnosis, for use in the method according to ~~any of~~ claim 18 to 25.

Preliminary Amendment
U.S. Patent Application No. 10/516,558

REMARKS/ARGUMENTS

Prior to payment of the filing fees, please enter the above amendment.

No questions of new matter are raised by the above amendment. Entry of the above amendment is therefore respectfully requested.

If there are any fees due in connection with the filing of this Preliminary Amendment, please charge the fees to Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,



Luke A. Kilyk
Registration No. 33,251

COPY

Attorney Docket No. 3190-071
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720

Date: January 25, 2005 Label No. EV567259572US I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Donald S. Prater
Name (Print)

Donald S. Prater / Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Chano et al.)	Examiner:	Unassigned
)		
Application No.:	10/516,558)	Group Art Unit:	Unassigned
)		
Filed:	November 30, 2004)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-070)	Customer No.:	33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

COPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 25, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear

Information Disclosure Statement
U.S. Patent Application No. 10/516,558


on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



COPY

Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-070
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/4 Documents

COPY

Page 1 of 1

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-070	Application No. 10/516,558
INFORMATION DISCLOSURE STATEMENT	APPLICANT: CHANO et al.	
	Filing Date: November 30, 2004	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	WO 00/55174	9/21/00	WIPO			X
	WO 00/78801 A2	12/28/00	WIPO			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Chano et al., "Identification of RB1CC1, a Novel Human Gene That Can Induce RB1 in Various Human Cells," ONCOGENE, Vol. 21 (2002), pp. 1295-1298.
	Chano et al., "Isolation, Characterization and Mapping of the Mouse and Human RB1CC1 Genes," GENE, Vol. 291 (2002) pp. 29-34.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: January 25, 2005 Label No. EV-7259572US I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Donald S. Prater
Name (Print)


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	CHANO et al.)	Examiner:	Unassigned
)		
Application No.:	10/516,558)	Group Art Unit:	Unassigned
)		
Filed:	November 30, 2004)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-070)	Customer No.:	33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

STATEMENT UNDER 37 C.F.R. § 1.821

COPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


January 25, 2005

Sir:

The diskette enclosed herewith contains a computer readable form of the Sequence Listing for the above-referenced patent application. The information recorded in computer readable form on the diskette is identical to the written sequences contained in the application as filed. The computer readable form of the sequence listing contained on this diskette is understood to comply with the requirements of 37 C.F.R. § 1.821(f). Also enclosed is a computer print-out of the sequence listing.

It is believed that no fee is required to make this complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No. 3190-070
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720

SEQUENCE LISTING

<110> Chano, Tokuhiro
Okabe, Hidetoshi
Ikegawa, Shiro

<120> RB1 gene induced protein (RB1CC1) and gene

<130> 3190-070

<140> US 10/516,558

<141> 2004-11-30

<150> PCT/JP03/00882

<151> 2003-01-30

<150> JP P2002-161400

<151> 2002-06-03

<150> JP P2002-214978

<151> 2002-07-24

<160> 132

<170> PatentIn version 3.1

<210> 1

<211> 1594

<212> PRT

<213> Unknown

<220>

<223> human RB1CC1

<400> 1

Met Lys Leu Tyr Val Phe Leu Val Asn Thr Gly Thr Thr Leu Thr Phe
1 5 10 15

Asp Thr Glu Leu Thr Val Gln Thr Val Ala Asp Leu Lys His Ala Ile
20 25 30

Gln Ser Lys Tyr Lys Ile Ala Ile Gln His Gln Val Leu Val Val Asn
35 40 45

Gly Gly Glu Cys Met Ala Ala Asp Arg Arg Val Cys Thr Tyr Ser Ala
50 55 60

Gly Thr Asp Thr Asn Pro Ile Phe Leu Phe Asn Lys Glu Met Ile Leu
65 70 75 80

Cys Asp Arg Pro Pro Ala Ile Pro Lys Thr Thr Phe Ser Thr Glu Asn
85 90 95

Asp Met Glu Ile Lys Val Glu Glu Ser Leu Met Met Pro Ala Val Phe
100 105 110

His Thr Val Ala Ser Arg Thr Gln Leu Ala Leu Glu Met Tyr Glu Val
115 120 125

Ala Lys Lys Leu Cys Ser Phe Cys Glu Gly Leu Val His Asp Glu His
130 135 140

Leu Gln His Gln Gly Trp Ala Ala Ile Met Ala Asn Leu Glu Asp Cys
145 150 155 160

Ser Asn Ser Tyr Gln Lys Leu Leu Phe Lys Phe Glu Ser Ile Tyr Ser
165 170 175

Asn Tyr Leu Gln Ser Ile Glu Asp Ile Lys Leu Lys Leu Thr His Leu
180 185 190

Gly Thr Ala Val Ser Val Met Ala Lys Ile Pro Leu Leu Glu Cys Leu
195 200 205

Thr Arg His Ser Tyr Arg Glu Cys Leu Gly Arg Leu Asp Ser Leu Pro
210 215 220

Glu His Glu Asp Ser Glu Lys Ala Glu Thr Lys Arg Ser Thr Glu Leu
225 230 235 240

Val Leu Ser Pro Asp Met Pro Arg Thr Thr Asn Glu Ser Leu Leu Thr
245 250 255

Ser Phe Pro Lys Ser Val Glu His Val Ser Pro Asp Thr Ala Asp Ala
260 265 270

Glu Ser Gly Lys Glu Ile Arg Glu Ser Cys Gln Ser Thr Val His Gln
275 280 285

Gln Asp Glu Thr Thr Ile Asp Thr Lys Asp Gly Asp Leu Pro Phe Phe
290 295 300

Asn Val Ser Leu Leu Asp Trp Ile Asn Val Gln Asp Arg Pro Asn Asp
305 310 315 320

Val Glu Ser Leu Val Arg Lys Cys Phe Asp Ser Met Ser Arg Leu Asp
325 330 335

Pro Arg Ile Ile Arg Pro Phe Ile Ala Glu Cys Arg Gln Thr Ile Ala
340 345 350

Lys Leu Asp Asn Gln Asn Met Lys Ala Ile Lys Gly Leu Glu Asp Arg
355 360 365

Leu Tyr Ala Leu Asp Gln Met Ile Ala Ser Cys Gly Arg Leu Val Asn
370 375 380

Glu Gln Lys Glu Leu Ala Gln Gly Phe Leu Ala Asn Gln Lys Arg Ala
385 390 395 400

Glu Asn Leu Lys Asp Ala Ser Val Leu Pro Asp Leu Cys Leu Ser His
405 410 415

Ala Asn Gln Leu Met Ile Met Leu Gln Asn His Arg Lys Leu Leu Asp
420 425 430

Ile Lys Gln Lys Cys Thr Thr Ala Lys Gln Glu Leu Ala Asn Asn Leu
435 440 445

His Val Arg Leu Lys Trp Cys Cys Phe Val Met Leu His Ala Asp Gln
450 455 460

Asp Gly Glu Lys Leu Gln Ala Leu Leu Arg Leu Val Ile Glu Leu Leu
465 470 475 480

Glu Arg Val Lys Ile Val Glu Ala Leu Ser Thr Val Pro Gln Met Tyr
485 490 495

Cys Leu Ala Val Val Glu Val Val Arg Arg Lys Met Phe Ile Lys His
500 505 510

Tyr Arg Glu Trp Ala Gly Ala Leu Val Lys Asp Gly Lys Arg Leu Tyr
515 520 525

Glu Ala Glu Lys Ser Lys Arg Glu Ser Phe Gly Lys Leu Phe Arg Lys
530 535 540

Ser Phe Leu Arg Asn Arg Leu Phe Arg Gly Leu Asp Ser Trp Pro Pro
545 550 555 560

Ser Phe Cys Thr Gln Lys Pro Arg Lys Phe Asp Cys Glu Leu Pro Asp
565 570 575

Ile Ser Leu Lys Asp Leu Gln Phe Leu Gln Ser Phe Cys Pro Ser Glu
580 585 590

Val Gln Pro Phe Leu Arg Val Pro Leu Leu Cys Asp Phe Glu Pro Leu
595 600 605

His Gln His Val Leu Ala Leu His Asn Leu Val Lys Ala Ala Gln Ser
610 615 620

Leu Asp Glu Met Ser Gln Thr Ile Thr Asp Leu Leu Ser Glu Gln Lys
625 630 635 640

Ala Ser Val Ser Gln Thr Ser Pro Gln Ser Ala Ser Ser Pro Arg Met
645 650 655

Glu Ser Thr Ala Gly Ile Thr Thr Thr Ser Pro Arg Thr Pro Pro
660 665 670

Pro Leu Thr Val Gln Asp Pro Leu Cys Pro Ala Val Cys Pro Leu Glu
675 680 685

Glu Leu Ser Pro Asp Ser Ile Asp Ala His Thr Phe Asp Phe Glu Thr
690 695 700

Ile Pro His Pro Asn Ile Glu Gln Thr Ile His Gln Val Ser Leu Asp
705 710 715 720

Leu Asp Ser Leu Ala Glu Ser Pro Glu Ser Asp Phe Met Ser Ala Val
725 730 735

Asn Glu Phe Val Ile Glu Glu Asn Leu Ser Ser Pro Asn Pro Ile Ser
740 745 750

Asp Pro Gln Ser Pro Glu Met Met Val Glu Ser Leu Tyr Ser Ser Val
755 760 765

Ile Asn Ala Ile Asp Ser Arg Arg Met Gln Asp Thr Asn Val Cys Gly
770 775 780

Lys Glu Asp Phe Gly Asp His Thr Ser Leu Asn Val Gln Leu Glu Arg
785 790 795 800

Cys Arg Val Val Ala Gln Asp Ser His Phe Ser Ile Gln Thr Ile Lys
805 810 815

Glu Asp Leu Cys His Phe Arg Thr Phe Val Gln Lys Glu Gln Cys Asp
820 825 830

Phe Ser Asn Ser Leu Lys Cys Thr Ala Val Glu Ile Arg Asn Ile Ile
835 840 845

Glu Lys Val Lys Cys Ser Leu Glu Ile Thr Leu Lys Glu Lys His Gln
850 855 860

Lys Glu Leu Leu Ser Leu Lys Asn Glu Tyr Glu Gly Lys Leu Asp Gly
865 870 875 880

Leu Ile Lys Glu Thr Glu Glu Asn Glu Asn Lys Ile Lys Lys Leu Lys
885 890 895

Gly Glu Leu Val Cys Leu Glu Glu Val Leu Gln Asn Lys Asp Asn Glu
900 905 910

Phe Ala Leu Val Lys His Glu Lys Glu Ala Val Ile Cys Leu Gln Asn
915 920 925

Glu Lys Asp Gln Lys Leu Leu Glu Met Glu Asn Ile Met His Ser Gln
930 935 940

Asn Cys Glu Ile Lys Glu Leu Lys Gln Ser Arg Glu Ile Val Leu Glu
945 950 955 960

Asp Leu Lys Lys Leu His Val Glu Asn Asp Glu Lys Leu Gln Leu Leu
965 970 975

Arg Ala Glu Leu Gln Ser Leu Glu Gln Ser His Leu Lys Glu Leu Glu
980 985 990

Asp Thr Leu Gln Val Arg His Ile Gln Glu Phe Glu Lys Val Met Thr
995 1000 1005

Asp His Arg Val Ser Leu Glu Glu Leu Lys Lys Glu Asn Gln Gln
1010 1015 1020

Ile Ile Asn Gln Ile Gln Glu Ser His Ala Glu Ile Ile Gln Glu
1025 1030 1035

Lys Glu Lys Gln Leu Gln Glu Leu Lys Leu Lys Val Ser Asp Leu
1040 1045 1050

Ser Asp Thr Arg Cys Lys Leu Glu Val Glu Leu Ala Leu Lys Glu
1055 1060 1065

Ala Glu Thr Asp Glu Ile Lys Ile Leu Leu Glu Glu Ser Arg Ala
1070 1075 1080

Gln Gln Lys Glu Thr Leu Lys Ser Leu Leu Glu Gln Glu Thr Glu
1085 1090 1095

Asn Leu Arg Thr Glu Ile Ser Lys Leu Asn Gln Lys Ile Gln Asp
1100 1105 1110

Asn Asn Glu Asn Tyr Gln Val Gly Leu Ala Glu Leu Arg Thr Leu
1115 1120 1125

Met Thr Ile Glu Lys Asp Gln Arg Ile Ser Glu Leu Ile Ser Arg
1130 1135 1140

His Glu Glu Glu Ser Asn Ile Leu Lys Ala Glu Leu Asn Lys Val
1145 1150 1155

Thr Ser Leu His Asn Gln Ala Phe Glu Ile Glu Lys Asn Leu Lys
1160 1165 1170

Glu Gln Ile Ile Glu Leu Gln Ser Lys Leu Asp Ser Glu Leu Ser
1175 1180 1185

Ala Leu Glu Arg Gln Lys Asp Glu Lys Ile Thr Gln Gln Glu Glu
1190 1195 1200

Lys Tyr Glu Ala Ile Ile Gln Asn Leu Glu Lys Asp Arg Gln Lys
1205 1210 1215

Leu Val Ser Ser Gln Glu Gln Asp Arg Glu Gln Leu Ile Gln Lys
1220 1225 1230

Leu Asn Cys Glu Lys Asp Glu Ala Ile Gln Thr Ala Leu Lys Glu
1235 1240 1245

Phe Lys Leu Glu Arg Glu Val Val Glu Lys Glu Leu Leu Glu Lys
1250 1255 1260

Val Lys His Leu Glu Asn Gln Ile Ala Lys Ser Pro Ala Ile Asp
1265 1270 1275

Ser Thr Arg Gly Asp Ser Ser Ser Leu Val Ala Glu Leu Gln Glu
1280 1285 1290

Lys Leu Gln Glu Glu Lys Ala Lys Phe Leu Glu Gln Leu Glu Glu
1295 1300 1305

Gln Glu Lys Arg Lys Asn Glu Glu Met Gln Asn Val Arg Thr Ser
1310 1315 1320

Leu Ile Ala Glu Gln Gln Thr Asn Phe Asn Thr Val Leu Thr Arg
1325 1330 1335

Glu Lys Met Arg Lys Glu Asn Ile Ile Asn Asp Leu Ser Asp Lys
1340 1345 1350

Leu Lys Ser Thr Met Gln Gln Gln Glu Arg Asp Lys Asp Leu Ile
1355 1360 1365

Glu Ser Leu Ser Glu Asp Arg Ala Arg Leu Leu Glu Glu Lys Lys
1370 1375 1380

Lys Leu Glu Glu Glu Val Ser Lys Leu Arg Ser Ser Ser Phe Val
1385 1390 1395

Pro Ser Pro Tyr Val Ala Thr Ala Pro Glu Leu Tyr Gly Ala Cys
1400 1405 1410

Ala Pro Glu Leu Pro Gly Glu Ser Asp Arg Ser Ala Val Glu Thr
1415 1420 1425

Ala Asp Glu Gly Arg Val Asp Ser Ala Met Glu Thr Ser Met Met
1430 1435 1440

Ser Val Gln Glu Asn Ile His Met Leu Ser Glu Glu Lys Gln Arg
1445 1450 1455

Ile Met Leu Leu Glu Arg Thr Leu Gln Leu Lys Glu Glu Glu Asn
1460 1465 1470

Lys Arg Leu Asn Gln Arg Leu Met Ser Gln Ser Met Ser Ser Val
1475 1480 1485

Ser Ser Arg His Ser Glu Lys Ile Ala Ile Arg Asp Phe Gln Val
1490 1495 1500

Gly Asp Leu Val Leu Ile Ile Leu Asp Glu Arg His Asp Asn Tyr
1505 1510 1515

Val Leu Phe Thr Val Ser Pro Thr Leu Tyr Phe Leu His Ser Glu
1520 1525 1530

Ser Leu Pro Ala Leu Asp Leu Lys Pro Gly Glu Gly Ala Ser Gly
1535 1540 1545

Ala Ser Arg Arg Pro Trp Val Leu Gly Lys Val Met Glu Lys Glu
1550 1555 1560

Tyr Cys Gln Ala Lys Lys Ala Gln Asn Arg Phe Lys Val Pro Leu
1565 1570 1575

Gly Thr Lys Phe Tyr Arg Val Lys Ala Val Ser Trp Asn Lys Lys
1580 1585 1590

Val

<210> 2
<211> 1588
<212> PRT
<213> Unknown

<220>
<223> mouse Rblcc1

<400> 2
Met Lys Leu Tyr Val Phe Leu Val Asn Thr Gly Thr Thr Leu Thr Phe
1 5 10 15

Asp Thr Glu Leu Thr Val Gln Thr Val Ala Asp Leu Lys His Ala Ile
20 25 30

Gln Ser Lys Tyr Lys Ile Ala Ile Gln His Gln Val Leu Val Val Asn
35 40 45

Gly Gly Glu Cys Met Ala Ala Asp Arg Arg Val Cys Thr Tyr Ser Ala
50 55 60

Gly Thr Asp Thr Asn Pro Ile Phe Leu Phe Asn Lys Glu Met Ile Leu
65 70 75 80

Cys Asp Arg Ala Pro Ala Ile Pro Lys Ala Thr Phe Ser Thr Glu Asn
85 90 95

Asp Met Glu Ile Lys Val Glu Glu Ser Leu Met Met Pro Ala Val Phe
100 105 110

His Thr Val Ala Ser Arg Thr Gln Leu Ala Val Glu Met Tyr Asp Val
115 120 125

Ala Lys Lys Leu Cys Ser Phe Cys Glu Gly Leu Val His Asp Glu His
130 135 140

Leu Gln His Gln Gly Trp Ala Ala Ile Met Ala Asn Leu Glu Asp Cys
145 150 155 160

Ser Asn Ser Tyr Gln Lys Leu Leu Phe Lys Phe Glu Ser Ile Tyr Ser
165 170 175

Asp Tyr Leu Gln Ser Ile Glu Asp Ile Lys Leu Lys Leu Thr His Leu
180 185 190

Gly Thr Ala Val Ser Val Met Ala Lys Ile Pro Leu Leu Glu Cys Leu
195 200 205

Thr Arg His Ser Tyr Arg Glu Cys Leu Gly Arg Pro Asp Ser Leu Asn
210 215 220

Glu His Glu Gly Ser Glu Lys Ala Glu Met Lys Arg Ser Thr Glu Leu
225 230 235 240

Val Leu Ser Pro Asp Met Pro Arg Thr Thr Asn Thr Ser Leu Val Thr
245 250 255

Ser Phe His Lys Ser Met Glu His Val Ala Pro Asp Pro Thr Gly Thr
260 265 270

Glu Arg Gly Lys Glu Leu Arg Glu Ser Cys Gln Ser Thr Val Gln Gln
275 280 285

Glu Glu Ala Ser Val Asp Ala Lys Asp Ser Asp Leu Pro Phe Phe Asn
290 295 300

Val Ser Leu Leu Asp Trp Ile Asn Val Gln Asp Arg Pro Asn Asp Val
305 310 315 320

Glu Ser Leu Val Arg Lys Cys Phe Asp Ser Met Ser Arg Leu Asp Pro
325 330 335

Lys Ile Ile Gln Pro Phe Met Leu Glu Cys His Gln Thr Ile Ala Lys
340 345 350

Leu Asp Asn Gln Asn Met Lys Ala Ile Lys Gly Leu Glu Asp Arg Leu
355 360 365

Tyr Ala Leu Asp Gln Met Ile Ala Ser Cys Ser Arg Leu Val Asn Glu
370 375 380

Gln Lys Glu Leu Ala Gln Gly Phe Leu Ala Asn Gln Met Arg Ala Glu
385 390 395 400

Asn Leu Lys Asp Ala Ser Val Leu Pro Asp Leu Cys Leu Ser His Ala
405 410 415

Asn Gln Leu Met Ile Met Leu Gln Asn His Arg Lys Leu Leu Asp Ile
420 425 430

Lys Gln Lys Cys Thr Thr Ala Lys Gln Glu Leu Ala Asn Asn Leu His
435 440 445

Val Arg Leu Lys Trp Cys Cys Phe Val Met Leu His Ala Asp Gln Asp
450 455 460

Gly Glu Lys Leu Gln Ala Leu Leu Arg Leu Val Ile Glu Leu Leu Glu
465 470 475 480

Arg Val Arg Ile Val Glu Ala Leu Ser Thr Val Pro Gln Met Tyr Cys
485 490 495

Leu Ala Val Val Glu Val Val Arg Arg Lys Met Phe Ile Lys His Tyr
500 505 510

Arg Glu Trp Ala Gly Ala Leu Val Lys Asp Gly Lys Gln Leu Tyr Glu
515 520 525

Ala Glu Lys Ser Lys Arg Glu Ser Phe Gly Lys Leu Phe Arg Lys Ser
530 535 540

Phe Leu Arg Asn Arg Leu Phe Lys Gly Leu Asp Ser Trp Pro Ser Ser
545 550 555 560

Phe Cys Thr Gln Lys Pro Arg Lys Phe Asp Cys Glu Leu Pro Asp Ile
565 570 575

Ser Leu Lys Asp Leu Gln Phe Leu Gln Ser Phe Cys Pro Ser Glu Val
580 585 590

Gln Pro Phe Leu Arg Val Pro Leu Leu Cys Asp Phe Glu Pro Leu His
595 600 605

Gln His Val Leu Ala Leu His Asn Leu Val Lys Ala Ala Gln Ser Leu
610 615 620

Asp Glu Met Ser Gln Thr Ile Thr Asp Leu Leu Asn Glu Gln Lys Val
625 630 635 640

Ser Thr Ser Gln Ala Ser Pro Gln Ser Ala Ala Ser Pro Arg Ile Glu
645 650 655

Ser Thr Thr Gly Ile Thr Thr Thr Ser Pro Lys Thr Pro Pro Pro
660 665 670

Leu Thr Val Gln Asp Thr Leu Cys Pro Ala Val Cys Pro Leu Glu Glu
675 680 685

Leu Ser Pro Asp Ser Ile Asp Ala His Thr Phe Asp Phe Glu Thr Ile
690 695 700

Ser His Pro Asn Thr Glu Gln Pro Val His Gln Ala Ser Ile Asp Leu
705 710 715 720

Asp Ser Leu Ala Glu Ser Pro Glu Ser Asp Phe Met Ser Ala Val Asn
725 730 735

Glu Phe Val Ile Glu Glu Asn Leu Ser Ser Pro Asn Pro Ile Ser Asp
740 745 750

Pro Gln Ser Pro Glu Met Met Val Glu Ser Leu Tyr Ser Ser Val Ile
755 760 765

Asn Ala Ile Asp Ser Arg Arg Met Gln Asp Thr Ser Thr Arg Gly Asn
770 775 780

Glu Gly Phe Gly Asp Arg Ala Ala Leu His Val Gln Leu Glu Lys Cys
785 790 795 800

Arg Ala Ala Ala Gln Asp Ser His Thr Ser Ile Gln Thr Ile Lys Asp
805 810 815

Asp Leu Cys His Phe Arg Thr Phe Val Gln Lys Glu Gln Cys Asp Leu
820 825 830

Ala Asn Tyr Leu Lys Cys Thr Ala Val Glu Ile Arg Asn Ile Ile Glu
835 840 845

Lys Val Lys Cys Ser Leu Glu Ile Thr Leu Lys Glu Lys His Gln Gln
850 855 860

Glu Leu Gln Ser Leu Lys Ile Glu Tyr Glu Cys Lys Leu Asp Ala Leu
865 870 875 880

Val Lys Asp Ser Glu Glu Asn Val Asn Lys Ile Leu Lys Leu Lys Glu
885 890 895

Asn Leu Val Ser Leu Glu Glu Ala Leu Gln Asn Lys Asp Asn Glu Phe
900 905 910

Thr Ser Ile Lys His Glu Lys Asp Ala Ile Val Cys Val Gln Gln Glu
915 920 925

Lys Asp Gln Lys Leu Leu Glu Met Glu Lys Ile Met His Thr Gln His
930 935 940

Cys Glu Ile Lys Glu Leu Lys Gln Ser Arg Glu Met Ala Leu Glu Asp
945 950 955 960

Leu Lys Lys Leu His Asp Glu Lys Ile Glu Ser Leu Arg Ala Glu Phe
965 970 975

Gln Cys Leu Glu Glu Asn His Leu Lys Glu Leu Glu Asp Thr Leu His
980 985 990

Ile Arg His Thr Gln Glu Phe Glu Lys Val Met Thr Asp His Asn Met
995 1000 1005

Ser Leu Glu Lys Leu Lys Lys Glu Asn Gln Gln Arg Ile Asp Gln
1010 1015 1020

Met Leu Glu Ser His Ala Ser Thr Ile Gln Glu Lys Glu Gln Gln
1025 1030 1035

Leu Gln Glu Leu Lys Leu Lys Val Ser Asp Leu Ser Asp Met Arg
1040 1045 1050

Cys Lys Leu Glu Val Glu Leu Ala Leu Lys Glu Ala Glu Thr Asp
1055 1060 1065

Glu Ile Lys Ile Leu Leu Glu Glu Ser Arg Thr Gln Gln Lys Glu
1070 1075 1080

Met Leu Lys Ser Leu Leu Glu Gln Glu Thr Glu Asn Leu Arg Thr
1085 1090 1095

Glu Ile Ser Lys Leu Asn Gln Lys Ile His Asp Asn Asn Glu Ser
1100 1105 1110

Tyr Gln Val Gly Leu Ser Glu Leu Arg Ala Leu Met Thr Ile Glu
1115 1120 1125

Lys Asp Gln Cys Ile Ser Glu Leu Ile Ser Arg His Glu Glu Glu
1130 1135 1140

Ser Asn Ile Leu Lys Ala Glu Leu Asp Asn Val Thr Ser Leu His
1145 1150 1155

Arg Gln Ala Tyr Glu Ile Glu Lys Lys Leu Lys Glu Gln Ile Val
1160 1165 1170

Glu Leu Gln Thr Arg Leu Asn Ser Glu Leu Ser Ala Leu Glu Lys
1175 1180 1185

Gln Lys Asp Glu Lys Ile Thr Gln Gln Glu Glu Lys Tyr Glu Ala
1190 1195 1200

Leu Ile Gln Asn Leu Glu Lys Asp Lys Glu Arg Leu Val Lys Asn
1205 1210 1215

His Glu Gln Asp Lys Glu His Leu Ile Gln Glu Leu Asn Phe Glu
1220 1225 1230

Lys Asn Lys Ala Val Gln Thr Ala Leu Asp Glu Phe Lys Val Glu
1235 1240 1245

Arg Glu Leu Val Glu Lys Glu Leu Leu Glu Lys Val Lys His Leu
1250 1255 1260

Glu Asn Gln Ile Ala Lys Thr Pro Ala Phe Glu Ser Ala Arg Glu
1265 1270 1275

Asp Ser Ser Ser Leu Val Ala Glu Leu Gln Glu Lys Leu Gln Glu
1280 1285 1290

Glu Lys Ala Lys Phe Leu Glu Gln Leu Glu Glu Gln Glu Lys Arg
1295 1300 1305

Lys Asn Glu Glu Met Gln Asn Val Arg Thr Ser Leu Ile Ala Glu
1310 1315 1320

Gln Gln Thr Asn Phe Asn Thr Val Leu Thr Arg Glu Lys Met Arg
1325 1330 1335

Lys Glu Asn Ile Ile Asn Asp Leu Ser Asp Lys Leu Lys Ser Thr
1340 1345 1350

Met Gln Gln Gln Glu Arg Asp Lys Asp Leu Ile Glu Ser Leu Ser
1355 1360 1365

Glu Asp Arg Ala Arg Leu Leu Glu Glu Lys Lys Gln Leu Glu Glu
1370 1375 1380

Glu Val Ser Lys Leu Arg Thr Ser Ser Phe Leu Ser Ser Ala Pro
1385 1390 1395

Val Ala Ala Ala Pro Glu Leu Tyr Gly Ala Cys Ala Pro Glu Leu
1400 1405 1410

Pro Gly Glu Pro Glu Arg Ser Val Met Glu Thr Ala Asp Glu Gly
1415 1420 1425

Arg Leu Asp Ser Ala Met Glu Thr Ser Met Met Ser Val Gln Glu
1430 1435 1440

Asn Met Leu Ser Glu Glu Lys Gln Arg Ile Met Leu Leu Glu Arg
1445 1450 1455

Thr Leu Gln Leu Lys Glu Glu Glu Asn Lys Arg Leu Asn Gln Arg
1460 1465 1470

Leu Met Ser Gln Ser Leu Ser Ser Val Ser Ser Arg His Ser Glu
1475 1480 1485

Lys Ile Ala Ile Arg Asp Phe Gln Val Gly Asp Leu Val Leu Ile
1490 1495 1500

Ile Leu Asp Glu Arg His Asp Asn Tyr Val Leu Phe Thr Val Ser
1505 1510 1515

Pro Thr Leu Tyr Phe Leu His Ser Glu Ser Leu Pro Ala Leu Asp
1520 1525 1530

Leu Lys Pro Gly Glu Gly Ala Ser Gly Ala Ser Arg Arg Pro Trp
1535 1540 1545

Val Leu Gly Lys Val Met Glu Lys Glu Tyr Cys Gln Ala Lys Lys
1550 1555 1560

Ala Gln Asn Arg Phe Lys Val Pro Leu Gly Thr Lys Phe Tyr Arg
1565 1570 1575

Val Lys Ala Val Ser Trp Asn Lys Lys Val
1580 1585

<210> 3

<211> 6636

<212> DNA

<213> Unknown

<220>

<223> human RB1CC1 gene

<400> 3
gtcgacaata acaaaccaag ccgcggcggt gtccgcggcc ctgcccggcc ctcggcggtt 60
cctcagaatc ccccaagtgc ctggggccct cggctctgac aggccgcggc cttctgtccc 120
ccggccccag acccagagcc gagggggctg ctcgcgtcct tgtccgcccc gaccctccc 180
tgcctcctag agttcggggc cgccggcggtt gggcgccccg gacgccggcg gtttgtcg 240
cttagcggtg ccgaatgggc gtttgtaac cgctgcccgg gactaggcg gggcgaaaga 300
tggtgccggg ggtcgctggc tctgctgctg ccgcggcgaa aggaggaggc gttgccgggtt 360
ttctgagttt aaccagtaat gccattcagt tgccaatctc aagcaaagca aacataagcc 420
agtttaatc tacttttaa gaaaagtggt agtccttttc acagtgcctg acgttaactgt 480
atcagagggt gaggtataag ctcacagaat tcagataat catcatgaag ttatatgtat 540
ttctggtaa cactggaact actctaacat ttgacactga acttacaggc caaactgtgg 600
cagaccttaa gcatgccatt caaagcaa atcaagattgc tattcaacac caggtgctgg 660
tggtaatgg aggagaatgc atggctgcag atcgaagagt gtgtacctac agtgcgtgg 720

cggatacaaa tccaatttt cttttaaca aagaatgat cttatgcgt cgccacctg	780
ctattcctaa aactaccctt tcgacagaaa atgacatgga aataaaagt gaagaatctc	840
ttatgatgcc tgcagtttt catactgtt cttcaaggac acagcttgca ttggaaatgt	900
atgaagttgc caagaaactt tgtttttt gtgaaggtct tgtacatgat gaacatctc	960
aacaccaagg ctgggctgca atcatggcca acctggagga ctgttcaa at tcataccaaa	1020
agctactttt caagttgaa agtatttatt caaattatct gcagtccata gaagacatca	1080
agttaaaact tactcattt ggaactgcag tttcagtaat gccaaagatt ccactgttgg	1140
agtgcctaac cagacatagt tacagagaat gtttggaaag actggattct ttacctgaac	1200
atgaagactc agaaaaagct gagacgaaaa gatccactga actggtgctc tctcctgata	1260
tgcctagaac aactaacgaa tctttgttaa cctcatttcc caagtcagtg gaacatgtgt	1320
ccccagatac cgccatgtct gaaagtggca aagaaattag ggaatcttgt caaagtactg	1380
ttcatcagca agatgaaact acgattgaca ctaaagatgg tgatctgccc ttttttaatg	1440
tctcttggta agactggata aatgttcaag atagacctaa tgatgtggaa tctttggta	1500
ggaagtgcct tgattctatg agcaggctt atccaaggat tattcgcacca tttatagcag	1560
aatgccgtca aactattgcc aaacttgata atcagaatat gaaagccatt aaaggacttg	1620
aagatcggtct acacccctg gaccagatga ttgcttagctg tggccgactg gtgaatgaac	1680
agaaagagct tgctcagggta ttttagcta atcagaagag agctgaaaac ttaaaggatg	1740
catctgtatt acctgattt tgcctgagtc acgcaaatca gttgatgatt atgttgcaaa	1800
atcatagaaa actgttagat attaagcaga agtgtaccac tgccaaacaa gaactagcaa	1860
ataacctaca tgtcagactg aagtgggttt gctttgtat gcttcatgtct gatcaagatg	1920
gagagaagtt acaagctttg ctccgcctcg taatagagct gttagaaaga gtcaaaattt	1980
ttgaagctct tagtacagtt cctcagatgt actgcttagc tggtgtttag gttgtaaagaa	2040
aaaaaatgtt cataaaacac tacagggagt gggctgggtc tttgtcaaa gatgaaaga	2100
gattatatga agcagaaaaa tcaaaaaggaa aatcctttgg gaaatttattt aggaagtctt	2160
ttttaaagaaa tcgtctgttt agggactgg actcctggcc cccttccttt tgtactcaaa	2220
agcctcgaaa gtttgactgt gaacttccag atatttcatt aaaagattt cagttctgc	2280
aatcatttttgc tccttcggaa gttcagccat tcctcagggt tcccttactt tgtgactttg	2340
aacctctaca ccagcatgta cttgctctac ataatttggtaaaaaggcagca caaagtttgg	2400

atgaaatgtc acagaccatt acagatctac tgagtgaaca aaaggcatct gtgagccaga	2460
catccccaca gtctgcttct tcaccaagga tggaaagtac agcaggaatt acaactacta	2520
cctcaccgag aactcctcca ccactgactg ttcaggatcc cttatgtcct gcagttgtc	2580
ccttagaaga attatctcca gatagtattt atgcacatac gtttgattt gaaactattc	2640
cccatccaaa catagaacag actattcacc aagtttcttt agacttggat tcattagcag	2700
aaagtcctga atcagattt atgtctgctg tgaatgagtt tgtaatagaa gaaaatttgt	2760
cgtctcctaa tcctataagt gatccacaaa gcccagaaat gatgggtggaa tcactttatt	2820
catcagttat caatgcgata gacagtagac gaatgcagga tacaaatgtt tgtggtaagg	2880
aggattttgg agatcatact tctctgaatg tccagttggaa aagatgtaga gttgttgc	2940
aagactctca cttcagtata caaaccatta aggaagacct ttgccactt agaacatttgc	3000
tacaaaaaga acagtgtgac ttctcaaatt cattaaaatg tacagcagta gaaataagaa	3060
acattattga aaaagtaaaa tggctctgg aaataacact aaaagaaaaa catcaaaaag	3120
aactactgtc tttaaaaaat gaatatgaag gtaaacttga cgactaata aagggaaactg	3180
aagagaatga aaacaaaatt aaaaaattga agggagagtt agtatgcctt gaggaggtt	3240
tacaaaataa agataatgaa tttgctttgg ttaaacatga aaaagaagct gtaatctgcc	3300
tgcagaatga aaaggatcag aagttgttag agatggaaaa tataatgcac tctcaaaatt	3360
gtgaaattaa agaactgaag cagtcacgag aaatagtgtt agaagactta aaaaagctcc	3420
atgtgaaaa tggatgagaag ttacagttat tgagggcaga acttcagtc ttggagcaaa	3480
gtcatctaaa ggaatttagag gacacacttc aggttaggca catacaagag tttgagaagg	3540
ttatgacaga ccacagagtt tctttggagg aattaaaaaa ggaaaatcaa caaataatta	3600
atcaaataca agaatctcat gctgaaatca tccagggaaaa agaaaaacag ttacaggaat	3660
taaaactcaa ggtttctgat ttgtcagaca cgagatgcaa gtttagagtt gaacttgcgt	3720
tgaaggaagc agaaactgat gaaataaaaa ttttgctgga agaaagcaga gcccagcaga	3780
aggagacctt gaaatctttt cttgaacaag agacagaaaa tttgagaaca gaaatttagta	3840
aactcaacca aaagattcag gataataatg aaaattatca ggtgggctta gcagagctaa	3900
gaactttaat gacaattgaa aaagatcagc gtatcccgat gtttaattttt agacatgaag	3960
aagaatctaa tatacttaaa gctgaaatca acaaagtaac atctttgcattt aaccaagcat	4020
ttgaaataga aaaaaaccta aaagaacaaa taattgaact gcagagtaaa ttggattcag	4080

aattgagtgc tcttcaaaga caaaaagatg aaaaaattac ccaacaagaa gagaaaatacg	4140
aagctattat ccagaacctt gagaaagaca gacaaaatt ggtcagcagc caggagcaag	4200
acagagaaca gttaattcag aagcttaatt gtgaaaaaga tgaagctatt cagactgcc	4260
taaaaagaatt taaattggag agagaagttg ttgagaaaga gttatttagaa aaagttaaac	4320
atcttgagaa tcaaatacgca aaaagtccctg ccattgactc taccagagga gattctcaa	4380
gcttagttgc tgaacttcaa gaaaagcttc aggaagaaaa agctaagttt ctagaacaac	4440
ttgaagagca agaaaaaaga aagaatgaag aaatgcaaaa tgttcgaaca tcttgattg	4500
cggaacaaca gaccaatttt aacactgttt taacaagaga gaaaatgaga aaagaaaaaca	4560
taataaatga tcttagtgat aagttgaaaa gtacaatgca gcaacaagaa cgggataaag	4620
atttgataga gtcactttct gaagatcgag ctcgttgct tgaggaaaag aaaaagcttgc	4680
aagaagaagt cagtaagttg cgcaatgcgca gttttgttcc ttcaccatat gtagctacag	4740
ccccagaact ttatggagct tgcgtcacccg aactcccagg tgaatcagat agatccgctg	4800
tggaaacagc agatgaagga agagtggatt cagcaatgga gacaagcatg atgtctgtac	4860
aagaaaaat tcatatgttgc tctgaagaaaa aacagcggat aatgctgtta gaacgaacat	4920
tgcaattgaa agaagaagaa aataaacggt taaatcaaag actgatgtct cagagcatgt	4980
cttcagttatc ttcaaggcat tctgaaaaaga tagctattag agatttcag gtggagatt	5040
tggtaactcat catcctagac gaacgcccattt acaattatgt gttatattact gttagtccta	5100
ctttatattt tctacattca gagtctctac ctgccttggaa tctcaaaccat ggtgagggtg	5160
cttcagggtgc atctagaaga ccctgggtac ttggaaaaagt aatggaaaaaa gaatactgtc	5220
aagccaaaaaa ggcacaaaaac agatttaaag ttcccttggg gacaaagttt tacagagtga	5280
aagccgtatc atggaataag aaagtataac ttatggacaa aattaataca ttctatgaca	5340
ttttttctg atttgccttgc cagtgtcat tcatacactcc aaaaacagca ggccatctt	5400
ttatgcaaaaa gtcagcgtga caatatactt cactggtgta catcggttac ttttaactg	5460
gtttcatttt aggaataata aattcatcag aatccttggc tgaattaaaa tggttttgt	5520
tttttgggtt tttttttac ccagacaact ctggaaatgc ggaccaaaact acttcatttt	5580
ctcaaagggc ataccttgttgc cattgtggct tatgtgagc catattaatt gcctgttaaa	5640
tatacacttag cttgaactta gatgttaaat gttatttata ccagcatttg tcctttgtg	5700
aaatcagttat cagaataactt gcactcttta acacatttttataaaaatgt ataaattatt	5760

cagaactatt	taaaataaag	aggagtgtt	ttgcatgctg	ataatcattt	tgagttgcc	5820	
tcagtagata	ctaaagcaaa	ttgtttcagt	ttttttaaat	gcccttgat	gtttcaaaaa	5880	
aaaaaaggaa	ctgtaattt	tgactgat	tttaagatca	gccataagta	atcagcaatc	5940	
ttcaaaagca	cttcagtg	ttggcattc	tgggttctaa	agggaagagt	ctgtgctact	6000	
aaccatttca	aatgcagact	caaacc	ttcc	caacatctt	atgactctag	aataatcata	6060
ttgatgaaat	cgtaattcat	ggtttagtt	cagaacaaaa	gatattcatt	gcacattaac	6120	
catttagagg	tcatttaaat	aacaaaat	tgtattgtaa	aagaactgta	caattttaaa	6180	
acaataaaga	tttgaacctg	taatgtgt	tgcc	ttttaa	agaaggatac	attttaata	6240
tatggatgt	attgctgg	agtgtgaaa	tattgttat	tatcatatca	aagagaaaca	6300	
tgtttattac	aaaaatgttc	tttaactata	tactatgtaa	caggtaaac	agtgttatgt	6360	
agaatagaat	tgtgtaaact	agatctttag	agaagttgcc	attgagcaaa	gttatttaaa	6420	
tgagtttagt	gagttggat	agaattgtt	gaggttgtt	gctagagaac	aataataaaa	6480	
taattctttt	tcagaaaata	tttaattct	tcataaaaat	aagttaaata	tttttttaaa	6540	
tatgtatatc	taatagtaca	aaatggaata	aacatcatag	tgtatagaaa	actgaattt	6600	
acaagttaat	gaataaatga	acaaatgatt	tcaaaa			6636	

<210> 4
 <211> 6518
 <212> DNA
 <213> Unknown

<220>
 <223> mouse Rblccl gene

<400> 4	ccgagtcgac	aataacaaac	cccacggcgg	ccgcgaccca	gccctgccaa	gctctcagtg	60
	cctcggccgg	cgactcg	ccccgcg	gagccgaggg	gccggagcag	cggctgcg	120
	cgactccat	cttccgggc	ctcgccgg	actcggcggc	tggcgc	cggttgtgtc	180
	ggttggcggc	gccgcagg	cggttgatag	ccgccc	ggccagg	gcggcagaag	240
	atggtgccga	ggccgc	ctgtgttg	gccgcgg	gaggagg	tgccgg	300
	ctgagttca	ccagtaatgc	cactcagtt	ccaatata	gcaagcg	catata	360
	tgtatctt	taagaaa	agtactt	tccacagt	ctggcgg	atc aacactgg	420
	ggtgagg	tgt	cagttccag	aaagatcatc	atgaagtt	atgtgttct	480

ggaaccacgc tgacatttg a cactgagcta actgtgcaaa ctgtggctga tcttaagcat	540
gccattcaaa gcaaatacaa gattgctatt cagcaccagg ttctgggtt caatggagga	600
gaatgcattgg ctgcagatcg aagagtgtgt acttacagcg ctgggacgga cacaatcca	660
attttcttt ttaataaaaga aatgatctta tgtgaccgtg cacctgctat tcctaaagct	720
acctttcaa cagaaaatga catggaaata aaagtgaag agtctttat gatgcctgca	780
gtttccaca ctgttgcttc aaggacacag cttgcagtgg aatgtatga cgttgccaag	840
aagctctgct ctttctgtga agggcttgc catgatgaac atcttcagca ccaaggctgg	900
gctgcaatca tggccaatct ggaggactgt tcaaattcat accaaaaact tctttcaag	960
tttggaaagta tttattctga ttatcttcaa tccatagaag acatcaagtt aaaacttact	1020
catttagaa ctgctgttcc agtaatggcc aagattccac tattggagtg cctaaccaga	1080
catagttaca gggaaatgttt gggaaagaccg gattcttga atgaacatga aggctcagag	1140
aaagctgaga tgaaaagatc tactgaactg gtgctctc ctgatatgcc tagaacaacg	1200
aacacatcct tggtaaccctc atttcacaag tcaatggagc atgttagctcc agatcccacc	1260
ggtactgaac gtggcaaaga acttagggaa tcttgtcaaa gtactgtcca gcaagaagaa	1320
gcttcagtgg atgctaaaga cagtgatctg cctttttta atgtttcttt gttagactgg	1380
ataaaatgttc aagatagacc caatgatgtg gaatctctgg tcaggaagtg ctggattct	1440
atgagcaggc ttgacccaaa gattattcaa ccatttatgt tagaatgcca tcaaactatt	1500
gccaaacttg ataatcagaa tatgaaagcc attaaaggc ttgaagatcg gctgtatgcc	1560
ttggaccaga tgattgctag ctgtagccgg ctggtaaatg aacagaaaga gcttgctcag	1620
ggattttag ctaatcagat gagagctgaa aacttgaagg atgcattgt gttacctgat	1680
ctgtgtctga gtcattgcaaa tcaactaatg attatgtgc aaaaccacag aaaactgttg	1740
gatattaaac agaagtgcac cactgccaaa caagagctag caaacaatct ccacgtcaga	1800
ctgaagtgg gttgtttgt gatgcttcat gctgatcaag atggagaaaa actgcaggca	1860
ctgctccgcc ttgtaataga gctgttagaa agagtcagaa ttgttgaggc tcttagtaca	1920
gttcctcaga tgtattgcct agctgtgtt gaggttgtaa gaagaaaaat gttcattaaa	1980
cactacagag agtgggctgg tgcttagtc aaagacggaa aacaactata tgaagctgaa	2040
aagtcaaaaa gggaaatcctt tggaaatattt ttttaggaagt ctttttaag aaatcgtctg	2100
ttaaaggac tggactcctg gccttcctca tttgtactc agaagcctcg aaaatttgac	2160

tgtgaacttc cagatatac attaaaagat ttacagttc ttcaatcatt ttgccttca	2220
gaagtgcagc cattcctcag ggtccccta ctttgact ttgaacctc acaccagcat	2280
gtacttgccc tacataattt ggtaaaagca gcacaaagtt tggatgaaat gtcacagact	2340
attacagatc tcctaaatga acaaaaggta tccacaagtc aggcattcccc acagtcagct	2400
gcttctcaa gaatagaaaag tacaacaggc attacaacca ctacctcacc aaaaactcct	2460
cctccactaa ctgttcagga caccttatgt ccggcagtgt gtcccttaga agaattatct	2520
ccagatagta tcgatgctca tacatttgat ttcgaaacca tctccatcc aaacacagaa	2580
caacctgttc accaagcttc tataacttg gattcattag cagaaagccc tgagtctgac	2640
tttatgtctg ctgtgaatga gtttgtata gaagaaaatt tatcgctcc aaaccctata	2700
agtgatccac aaagtccaga aatgatggtg gagtcacttt actcttcagt catcaatgca	2760
atagatagta ggcgtatgca agacacaagt acacgtggaa acgaggcgtt tgggatcgg	2820
gctgctctac atgtccagct ggagaaatgc agagctgctg cacaagactc tcacaccagt	2880
atacaaacca tcaaggacga tctgtgccat ttcagaacat ttgtacaaaa agaacagtgt	2940
gacttagcaa attattnaaa atgtacagct gtagaaataa gaaatattat tggaaaaatgt	3000
aatgttctc tagaaataac actaaaggaa aagcatcagc aagaactcca atctttaaaa	3060
attgagtagt aatgtaaact tgatgctcta gtaaaagaca gtgaagaaaa tggaaataaaa	3120
attttaaaat tgaaagaaaa ttttagtatcc cttgaagagg ctttacaaaa taaagacaat	3180
gaattcactt cgattaaaca tgaaaaggat gctattgtct gtgtgcagca agaaaaggat	3240
cagaagttgt tagagatgga aaagataatg catactcaac attgtgaaat taaagaactg	3300
aagcagtcac gagagatggc attagaagac ctgaaaaagc tgcatgatga aaaaatcgag	3360
tcattgagag ctgaatttca gtgcttagaa gaaaatcacc tgaaggaatt agaggacaca	3420
ctgcacatca ggcacacaca ggagtttgag aaagttatga cagaccacaa tatgtcttg	3480
gagaaattaa aaaaagaaaa tcagcaaaga attgaccaga tgctagaatc tcatgcctca	3540
actattcagg aaaaagagca acagctgcag gagttgaaac tcaaagttc tgacttgtca	3600
gacatgagat gtaagttaga ggtgaactt gcactaaagg aagcagaaac agatgagata	3660
aagatcttgt tggaaagagag cagaacacag cagaaggaaa tgctgaagtc tttacttgaa	3720
caagagaccg aaaacttaag aacagaaata agtaaactaa accaaaaaat tcatgataat	3780
aatgagagtt accaggtggg tttgtcagag ttaagagctt taatgacaat tgaaaaagat	3840

cagtgcattt cagagtaat cagtagacat gaagaagaat ctaatatact taaggctgaa	3900
ttagacaatg ttacatcttt gcatcgccaa gcatatgaaa tagaaaaaaaaa actgaaagaa	3960
caaatagttg aattgcagac tagattgaac tcagaattga gtgctcttga aaaacagaaa	4020
gatgaaaaaaaaa ttacccaaca agaagagaag tatgaagcac ttatccagaa ccttgagaaa	4080
gacaaggaga gactggtcaa gaaccacgag caagacaaag aacacttaat tcaggagctt	4140
aattttgaaa aaaacaaagc tttcaact gcactagatg aatttaaggt ggagagagaa	4200
cttgttggaa aagagttatt agaaaaagtt aaacatcttg agaatcaaact agccaaaact	4260
cctgcctttg agtcagccag agaagattct tcaagcttag ttgcggaaact tcaagagaaa	4320
cttcaagaag aaaaagctaa gtttctggaa caacttgaag aacaagagaa aagaaagaat	4380
gaggaaatgc aaaatgtcag aacctctttg attgctgagc agcagaccaa cttaacaca	4440
gtcttaacaa gagagaaaat gaggaaagaa aacataataa atgatcttag tgataagcta	4500
aaaagtacaa tgcagcagca agagcgggat aaagatttga tagagtcgct ctctgaggac	4560
cgagctcggt tgcttgaaga gaagaagcag cttgaagagg aagtgagtaa actccgact	4620
agcagtttc tttcctcagc acctgtggct gcagccccag agctctatgg tgcgttgca	4680
cctgagctcc caggggagcc agagagatca gtcatggaga cggcagatga aggaagactg	4740
gattccgcaa tggagacaag catgatgtct gtccaaagaaa acatgttatac tgaagagaag	4800
cagaggatca tgctcctaga acggacattt cagttgaaag aagaagaaaa caagcggta	4860
aatcaaagac tcatgtctca gagtttgc tcaagtctttt caaggcattt tgaaaaata	4920
gccatttagag atttcaggt gggagattt gttctcatca tcctagatga gcggcacgac	4980
aattatgtat tgtttactgt tagtcctact ttatattttc tgcactcaga gtctttccct	5040
gccctggatc tcaaaccagg tgaggagct tcaggtgcattt ctgggtcctt	5100
ggaaaagtaa tggaaaagga atactgtcaa gccaaaaagg cacaaaacag atttaaagtt	5160
ccttgggaa caaagttta cagagtggaa gctgtgtcat ggaataagaa agtatacgca	5220
cagaagaaat ctctacatct cataccattt ttgatttgc ctccagtgc gataaactac	5280
tctaaaaaca gctggccatt gttgggtttt tttttgtgt ttgtttgtt gtttgggtttt	5340
acaaaagtca acataacaat atacttcatt ggtggactgc acttacctt taagtggcta	5400
catcttagga acaataaatt tattaaaatt cttggctgaa tcaaaatggt tttgtttgt	5460
ttccacccaa ataactagaa attcggacca aaatagatgt tttccaaggg cagagcctgc	5520

actgtggctt	gtgactagcc	tcattagttg	cctgttaata	aacattagct	gaatagttac	5580
cagtgttgtt	accagcattt	gtcctcttgt	gaattcaaga	gtcctcgac	tctttaacat	5640
gttctttata	aatgtataa	acccttccaa	actattaaa	gaggagtgtt	attgcattgca	5700
gataatcata	attttagttt	tgcctcagaa	gactactaaa	gcaaatttgt	tcatttttt	5760
ttaaaaaat	gcccttaat	gtttcaaaaa	aaaataacag	tgtaatttga	ctgactttaa	5820
gatcagccat	aaataatgag	cagtcttcaa	aagcactttt	cacacagatc	atctgggctc	5880
cagggaggaa	gagtctgtgc	cactgatgtt	ttcaagtgc	ggactcactc	aaacctctca	5940
gcacatctttagg	actgtttcaa	gtaatcatat	tgtgaactc	gtaattcatg	gttgaccttc	6000
agaagaagat	attcatttta	tattaacatt	tagaggtcat	ttaaataaca	aaagtctgt	6060
ttgttaaagga	cctgtacaat	tttaagacaa	taaagaattt	aaagtgtaaa	tgtgtgtgcc	6120
ttttaaaggt	tacattttaa	atataattgcg	tgatttctgg	gaaaggtgaa	aaaaatgttc	6180
tgtatcaaag	agaaacctgt	ttattaaaaa	atgttgtttt	tatcctatgt	aacaggggt	6240
agtgggtttc	tgtggAACAG	aaccatgtaa	actcaagggtt	taaaagctgg	cactgaacaa	6300
agatattgaa	gtagctaggc	tagttgattt	gaaagagttt	cttcagggtt	gttggtagca	6360
gtaataaaatg	attcttttc	agaaatattt	aatttctcca	taaaaataag	ttggatattt	6420
ttataaaatat	gtaatcta	agaatgaaaa	tggaaaaaac	atagtgtata	gaatacctaa	6480
ttcaaaaaca	tattaatgaa	taaacgaaca	aatgattt			6518

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> artificially synthesized primer sequence called CC1-S1

<400> 5
 gacgttaactg tatcagaggg 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> artificially synthesized primer sequence called CC1-S2

<400> 6		
tcagagggtg aggtataa	gc	20
<210> 7		
<211> 28		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called CC1-S3		
<400> 7		
atcatcatga agttatatgt atttctgg		28
<210> 8		
<211> 21		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called CC1-ASP2		
<400> 8		
ttggccatta ctgaaactgc a		21
<210> 9		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called CC1-S4		
<400> 9		
tgtggaatct ttggcagga		20
<210> 10		
<211> 21		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called CC1-ASP1		
<400> 10		
taatccttgg atcaagcctg c		21
<210> 11		
<211> 21		
<212> DNA		
<213> Artificial		

<220>
<223> artificially synthesized primer sequence called CC1-S5

<400> 11
tgttaccactg ccaaacaaga a 21

<210> 12
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S6

<400> 12
cttcggaaagt tcagccattc 20

<210> 13
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S6R

<400> 13
tccatccttg gtgaagaagc 20

<210> 14
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S7

<400> 14
tccccatcca aacatagaaac a 21

<210> 15
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S8

<400> 15
aaggaaagacc tttgccactt t 21

<210> 16
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S9

<400> 16
gaactgaagc agtcacgaga aa 22

<210> 17
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S10

<400> 17
ttgtcagaca cgagatgcaa 20

<210> 18
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S11

<400> 18
aaattatccat gtgggcttag ca 22

<210> 19
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-S

<400> 19
ccaggagcaa gacagagaac 20

<210> 20
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-AS

<400> 20
cgagctcgat ctgcagaaag 20

<210> 21
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-AS5

<400> 21
tgcttgtctc cattgctgaa 20

<210> 22
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-AS4

<400> 22
ccaaatctcc cacctgaaaa 20

<210> 23
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called HCC22INTS

<400> 23
ctagacgaac gccatgacaa 20

<210> 24
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called HCC22INTAS

<400> 24
tggcttgaca gtattcttt tcc 23

<210> 25
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-AS2

<400> 25
tgagcactgc aggacaaaatc a 21

<210> 26
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called CC1-AS1

<400> 26
tgcgtttttt gcaatgcagg a 21

<210> 27
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-RS1

<400> 27
cctccctgcc tccttagatg 20

<210> 28
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-R4

<400> 28
tagtcctcggt cagcggttac 20

<210> 29
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-R3

<400> 29
aaactcagaa aaccggcaac 20

<210> 30
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-R2

<400> 30
tgccacagtt tgcactgtaa g 21

<210> 31
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-R1

<400> 31
tttccaatgc aagctgtgtc 20

<210> 32
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-RS2

<400> 32
gagtgaaaagc cgtatcatgg a 21

<210> 33
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-RS3

<400> 33
aatgcggacc aaactacttc a 21

<210> 34
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called on RB1CC-RS4

<400> 34
tcagtggatt ggtcatctgg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-RS5

<400> 35
tgattgctgg gaagtgtgaa 20

<210> 36
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-RS6

<400> 36
gagaatttgtt tgaggtttgt tgc 23

<210> 37
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called RB1CC-R5

<400> 37
ttgctcaatg gcaacttctc 20

<210> 38
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK3-1-S

<400> 38
gggtgaggta taagctcaca gaa 23

<210> 39
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK3-2-S

<400> 39
tcttatgtga tcgtccacct g 21

<210> 40
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK3-2-AS

<400> 40
caaaggattc ccttttgat ttt 23

<210> 41
<211> 26
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK6-2-S

<400> 41
gctaattcaga agagagctga aaactt 26

<210> 42
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK1-1-S

<400> 42
gatgggtgatc tgccctttt 20

<210> 43
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK1-2-S

<400> 43
taagcatgcc attcaaagca 20

<210> 44
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK15-1-S

<400> 44
tttctttata caggaaatc ttt 23

<210> 45
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK15-2-AS

<400> 45
ttttcagaat gccttgaaga t 21

<210> 46
<211> 23
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK31-2-S

<400> 46
aggataccat catccttagac gaa 23

<210> 47
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK31-2-AS

<400> 47
cttaccaccc tcacctgggt 20

<210> 48
<211> 26
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MMK40-S

<400> 48		
ttttgttattt taagtttagg aactgc		26
<210> 49		
<211> 23		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MMK38-S		
<400> 49		
ataggataca aatccaaattt ttc		23
<210> 50		
<211> 27		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MMK31-S		
<400> 50		
aaaatatagg atacaaatcc aatgaca		27
<210> 51		
<211> 24		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MMK36-S		
<400> 51		
aaaggatgca tctgtattac ctga		24
<210> 52		
<211> 19		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MMK340-S1		
<400> 52		
gccaacctgg aggactgtt		19
<210> 53		
<211> 23		
<212> DNA		
<213> Artificial		

<220>		
<223>	artificially synthesized primer sequence called MCC-S1	
<400> 53	ggttctctga gtttcaccag taa	23
<210> 54		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223>	artificially synthesized primer sequence called MCC-S2	
<400> 54	atcaaacactg gaggggtgagg	20
<210> 55		
<211> 28		
<212> DNA		
<213> Artificial		
<220>		
<223>	artificially synthesized primer sequence called EcoCC1S3	
<400> 55	atcatcatga agttataatgt gtttctgg	28
<210> 56		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223>	artificially synthesized primer sequence called MCC-S7	
<400> 56	gatgccttgca gttttccaca	20
<210> 57		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223>	artificially synthesized primer sequence called MCC-S8	
<400> 57	acgtggcaaa gaacttaggg	20

<210> 58
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-AS4

<400> 58
gcttcttcctt gctggacagt 20

<210> 59
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-S11

<400> 59
ccttggacca gatgattgct 20

<210> 60
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-S9

<400> 60
gggtccccc tt actttgtgac t 21

<210> 61
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-AS8

<400> 61
catccaaact ttgtgctgct 20

<210> 62
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-S12

<400> 62		
tgctgcacaa gactctcaca		20
<210> 63		
<211> 21		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-AS6		
<400> 63		
ggcacagatc gtccttgatg g		21
<210> 64		
<211> 21		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-S13		
<400> 64		
tgaacttgca ctaaaggaag ca		22
<210> 65		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-AS7		
<400> 65		
cagcatttcc ttctgctgtg		20
<210> 66		
<211> 24		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-S14		
<400> 66		
tgagtgctct tgaaaaacag aaag		24
<210> 67		
<211> 21		
<212> DNA		
<213> Artificial		

<220>		
<223> artificially synthesized primer sequence called MCC-S15		
<400> 67		
ttgcggaact tcaagagaaa c		21
<210> 68		
<211> 24		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MIRB1CC-5		
<400> 68		
ctggaacaac ttgaagaaca agag		24
<210> 69		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MIRB1CC-3		
<400> 69		
acgagctcggtc tcctcagaga		20
<210> 70		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-S3		
<400> 70		
tcaggtggaa gatttggttc		20
<210> 71		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MCC-AS3		
<400> 71		
tgcgcgtcat cttaggtat		20

<210> 72
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-AS2

<400> 72
cagcactgga ggacaaatca 20

<210> 73
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-AS1

<400> 73
agtccacaagg cacagtgcag 20

<210> 74
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-ASR1

<400> 74
tgctttgaat ggcattgttta 20

<210> 75
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-ASR2

<400> 75
cctcacccctc cagtgttgat 20

<210> 76
<211> 18
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-ASR3

<400> 76
cctccgcacc atcttctg 18

<210> 77
<211> 18
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called INTRON1ASR

<400> 77
cagggtcccc gtaggact 18

<210> 78
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-SR1

<400> 78
tcaggtggga gatttggttc 20

<210> 79
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized priemr sequence called MCC-SR2

<400> 79
ccagcatttg tcctcttgt 20

<210> 80
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC3=S3

<400> 80
ttttgagttt gcctcagaag a 21

<210> 81
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC3-S4

<400> 81
tcggaattca tggttgacct 20

<210> 82
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC3-AS2

<400> 82
tttcccagaa atcacgcaat 20

<210> 83
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC3-AS13

<400> 83
tctttgttca gtgccagctt t 21

<210> 84
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC15S

<400> 84
accagggtggg tttgtcagag 20

<210> 85
<211> 20
<212> DNA
<213> Artificial

<223> artificially synthesized primer sequence called MCC15AS

<400> 85
cttggcgatg caaagatgta 20

<210> 86
<211> 20

<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-3S

<400> 86
acactggagg gtgaggtgtc 20

<210> 87
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MCC-3AS

<400> 87
gtgtcaaatg tcagcgttgt 20

<210> 88
<211> 18
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT1-S

<400> 88
gacggttgtg tcggttgg 18

<210> 89
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT1-AS

<400> 89
ttggcaactg agtggcatta 20

<210> 90
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT2-S0

<400> 90
tgccacttag ttgccaagta 20

<210> 91
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT2-S

<400> 91
cacagtatct ggccgttaagt ca 22

<210> 92
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT3-AS

<400> 92
cccagcgctg taagtacaca 20

<210> 93
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT4-S

<400> 93
taagcatgcc attcaaagca 20

<210> 94
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT4-AS

<400> 94
caggtgcacg gtcacataag 20

<210> 95
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT5-S

<400> 95
gcagtttcc acactgttgc 20

<210> 96
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT5-AS

<400> 96
ctccagattg gccatgattg 20

<210> 97
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT6-S

<400> 97
gccaatctgg aggactgttc 20

<210> 98
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT6-AS

<400> 98
agaatccggt cttcccaaac 20

<210> 99
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT7-S

<400> 99
cccaatgatg tggaatctct g 21

<210> 100
<211> 20
<212> DNA
<213> Artificial

<220>		
<223> artificially synthesized primer sequence called MINT7-AS		
<400> 100		
agcaatcatc tggtccaagg		20
<210> 101		
<211> 19		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MINT8-S		
<400> 101		
aagatcggt gtatgcctt		19
<210> 102		
<211> 22		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MINT8-AS		
<400> 102		
caacagtttt ctgtgggttt gc		22
<210> 103		
<211> 21		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MINT9-S		
<400> 103		
ggatgcacatc gtgttacctg a		21
<210> 104		
<211> 20		
<212> DNA		
<213> Artificial		
<220>		
<223> artificially synthesized primer sequence called MINT9-AS		
<400> 104		
gcctgcagtt tttctccatc		20

<210> 105
<211> 20
<212> DNA
<213> Artificial
<220>
<223> artificially synthesized primer sequence called MINT10-S

<400> 105
gctccgcctt gtaatagagc 20

<210> 106
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT10-AS

<400> 106
ccaaaggatt cccttttga 20

<210> 107
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT11-S

<400> 107
gggctgggtgc tttagtcaaa 20

<210> 108
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT11-AS

<400> 108
aaaatgagga aggccaggag 20

<210> 109
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT12-S

<400> 109
actcctggcc ttcctcattt 20

<210> 110
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT12-AS

<400> 110
tgaggaatgg ctgcacttct 20

<210> 111
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT13-S

<400> 111
gcctcgaaaa tttgactgtg a 21

<210> 112
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT13-AS

<400> 112
tccaaacttt gtgctgcttt t 21

<210> 113
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT14-S

<400> 113
aaaaggcagca caaagtttgg a 21

<210> 114
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT14-AS

<400> 114
tggaggagga gtttttggtg 20

<210> 115
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT15-S

<400> 115
ccacgagcaa gacaaagaac 20

<210> 116
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT15-AS

<400> 116
tccgcaacta agcttgaaga a 21

<210> 117
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT16-S

<400> 117
tgaggaaatg caaaaatgtca 20

<210> 118
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT16-AS

<400> 118
gctcttgctg ctgcattgt 20

<210> 119
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT17-S

<400> 119
aaagtacaat gcagcagcaa ga 22

<210> 120
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT17-AS

<400> 120
tgctgaggaa agaaaactgc t 21

<210> 121
<211> 19
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT18-S

<400> 121
agctctatgg tgcgtgtgc 19

<210> 122
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT18-AS

<400> 122
gagcatgatc ctctgcttct c 21

<210> 123
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT19-S

<400> 123
tctgaagaga agcagaggat ca 22

<210> 124
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence calle MINT19-AS

<400> 124
cagtcttgta tttaaccgct tg 22

<210> 125
<211> 24
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized priemr sequence called MINT20-S

<400> 125
cattgcagtt gaaagaagaa gaaa 24

<210> 126
<211> 21
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT20-AS

<400> 126
tgccttgaag agactgagga c 21

<210> 127
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT21-S

<400> 127
tctcttcaag gcattctgaa aa 22

<210> 128
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT21-AS

<400> 128
atccaggcga ggaagagact 20

<210> 129
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT22-S

agcggcacga caattatgt 20

<210> 130
<211> 22
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT22-AS

<400> 130
ttttccatta ctttcccaag ga 22

<210> 131
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT23-S

<400> 131
ctgggtcctt gggaaagtaa 20

<210> 132
<211> 20
<212> DNA
<213> Artificial

<220>
<223> artificially synthesized primer sequence called MINT23-AS

<400> 132
cagcactgga ggacaaatca 20